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resumo 
 
 
Feocromocitomas (FEO) e paragangliomas (PGL) são tumores 
neuroendócrinos raros que derivam do tecido paragangliónico do sistema 
nervoso autónomo, surgindo mais especificamente da medula adrenal – 
feocromocitomas – ou da paraganglia extra-adrenal – paragangliomas. Estes 
tumores são normalmente esporádicos, mas podem ocorrer como parte de 
diferentes síndromes tumorais hereditárias. 
Até à data, foram identificados dez genes que predispõem ao desenvolvimento 
de FEO e PGL: genes do complexo succinato desidrogenase (SDHA, SDHB, 
SDHC e SDHD); cofactor do complexo SDH (SDHAF2); RET, VHL, NF1, 
TMEM127 e MAX. 
O objectivo deste trabalho consistiu na identificação de alterações genéticas 
causais em duas séries de pacientes com FEO e PGL. Para tal, foi feita a 
pesquisa de alterações nos genes SDH, SDHAF2, RET, VHL, TMEM127 e 
MAX. Para além disso, foi analisada a expressão da proteína SDH por 
imunohistoquímica. 
Numa série composta apenas por FEO’s, a maioria dos pacientes foram 
identificados como esporádicos (82%), enquanto dois apresentavam síndrome 
MEN2 (4%) com mutações no gene RET, quatro com NF1 (7%) e um com VHL 
(2%); para além destes, três casos (5%) mostraram ausência de expressão de 
SDH, um deles com mutação. Não foram encontradas alterações genéticas 
patogénicas nos genes TMEM127 e MAX. 
Numa série de casos Portugueses constituída por FEO’s e PGL’s, seis 
pacientes (50%) foram identificados com mutação: quatro no gene SDHB e um 
no gene SDHD; adicionalmente, uma mutação patogénica foi identificada no 
gene MAX. Toda a informação clínica, genética e imunohistoquímica foi 
relacionada, provando que um diagnóstico baseado em estudos genéticos e 
imunohistoquímicos constitui o melhor método para pacientes com FEO/PGL’s. 
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abstract 
 
Pheochromocytomas (PCC) and paragangliomas (PGL) are rare 
neuroendocrine tumours derived from the paraganglionic tissue of the 
autonomic nervous system, arising more specifically from adrenal medulla - 
pheochromocytomas - or from extra-adrenal paraganglia - paragangliomas. 
These tumours are usually sporadic, but can occur as part of different 
hereditary tumour syndromes. 
To date, ten genes have been identified to predispose to the development of 
PCC and PGL: succinate dehydrogenase (SDH) complex subunit genes 
(SDHA, SDHB, SDHC and SDHD); SDH complex cofactor SDHAF2; RET, 
VHL, NF1, TMEM127 and MAX. 
The aim of this work was to identify the causative genetic defects in two series 
of PCC and PGL patients. For this purpose, genetic screening was performed 
for SDH, SDHAF2, RET, VHL,TMEM127 and MAX genes. Also, SDH protein 
expression was assessed by immunohistochemistry. 
In a series composed only of PCC’s, the majority of patients were sporadic 
(82%), while two had MEN2 (4%) with RET mutations, four had NF1 (7%) and 
one patient presented VHL (2%); furthermore, three patients (5%) showed 
absence of SDH, one with mutation. Pathogenic genetic defects in TMEM127 
and MAX were not found. 
In a Portuguese series comprising both PCC and PGL’s, six patients (50%) 
were found to have germline mutations: four in SDHB and one in SDHD; 
additionally, one pathogenic mutation was identified in MAX gene. Clinical, 
genetic and immunohistochemical data was associated, proving that a 
diagnosis based on genetic and immunohistochemical studies is a suitable 
approach for the management of PCC/PGL’s patients. 
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ANS - Autonomic Nervous System; 
ATP - Adenosine triphosphate; 
bHLHZip - Basic helix-loop-helix leucine zipper; 
COX - Cytochrome c oxidase; 
CS - Citrate synthase; 
CybL - Cytochrome b succinate dehydrogenase large subunit; 
CybS - Cytochrome b succinate dehydrogenase small subunit; 
DNA - Desoxyribonucleic acid; 
dNTP - Deoxyribonucleotide triphosphate; 
FAD – Flavin adenine dinucletotide; 
FADH2 – Flavin adenine dinucleotide (reduced form); 
GDNF - Glial cell line-derived neurotropic factor family; 
GIST - Gastrointestinal stromal tumours; 
GTP - Guanosine triphosphate; 
HIF - Hypoxia inducible factor; 
LOH – Loss of heterozygosity; 
MAX - Myc-associated factor X; 
MEN2 – Multiple endocrine neoplasia type 2; 
MLPA - Multiplex ligation-dependent probe amplification; 
MTC - Medullary thyroid carcinoma; 
mtDNA – Mitochondrial DNA; 
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mTOR - Mechanistic target of rapamycin; 
NAD – Nicotinamide adenine dinucleotide;  
NADH – Nicotinamide adenine dinucleotide (reduced form); 
NF1 – Neurofibromatosis type 1; 
PCC – Pheochromocytoma; 
PCR – Polymerase chain reaction; 
PGL – Paraganglioma; 
PHD - Prolyl hydroxylases; 
PSNS - Parasympathetic nervous system; 
PTC - Papillary thyroid carcinoma; 
RCC - Renal cell carcinoma; 
RET – Rearranged during transfection; 
Rheb - Ras homolog enriched in brain; 
ROS - Reactive oxygen species; 
SDH - Succinate dehydrogenase; 
SDHA – Succinate dehydrogenase subunit A; 
SDHAF1 - Succinate dehydrogenase complex assembly factor 1; 
SDHAF2 - Succinate dehydrogenase complex assembly factor 2; 
SDHB – Succinate dehydrogenase subunit B; 
SDHC – Succinate dehydrogenase subunit C; 
SDHD – Succinate dehydrogenase subunit D; 
GLOSSARY 
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SNP – Single nucleotide polymorphism; 
SNS - Sympathetic nervous system; 
S6K - Ribosomal protein S6 kinase; 
TCA – Tricarboxylic acid cycle; 
TMEM127 - Transmembrane protein 127; 
tRNA – Transfer RNA; 
TSC - Tuberous sclerosis protein; 
UPD – Uniparental disomy; 
VDAC - Voltage-dependent anion channel; 
VEGF - Vascular endothelial growth factor; 
VHL – Von Hippel-Lindau; 
4EBP1 - Eukaryotic translation initiation factor 4E binding protein 1. 
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PHEOCHROMOCYTOMAS, PARAGANGLIOMAS AND THE AUTONOMIC NERVOUS 
SYSTEM 
Pheochromocytomas (PCC) and paragangliomas (PGL) are rare neuroendocrine tumours derived 
from the paraganglionic tissue of the Autonomic Nervous System (ANS) (DeLellis 2004). 
The ANS comprises the sympathetic (SNS) and parasympathetic (PSNS) divisions forming the 
neural circuitry and working with neuroendocrine system for homeostasis regulation and body’s 
physiology control. The SNS enhances catabolic activities specially energy mobilization, whereas PSNS 
stimulates anabolic processes like promoting rest and reducing energy use (Squire et al. 2008). 
The SNS and PSNS are organized in pre-ganglionic neurons with cell bodies within the central 
nervous system (brain stem and spinal cord) and post-ganglionic motor neurons that project to the 
effector tissues. The SNS has pre-ganglionic neurons in the thoracic and lumbar regions of the spinal 
cord (T1 – L2) that in turn project to postganglionic motor neurons in paravertebral, prevertebral 
autonomic ganglia and chromaffin cells of adrenal medulla; the PSNS has preganglionic neurons in 
brain stem (cranial nerves III, VII, IX, X) and in the sacral spinal cord (S2, S3, S4) that project to 
postganglionic motor neurons in ganglia near or inside the viscera (Squire et al. 2008). 
The adrenal medulla is the one exception to the two-neuron pathway rule since post-ganglionic 
nerve cells are classical neurosecretory cells. They secrete postganglionic sympathetic transmitters, 
catecholamines, directly into the bloodstream (Nussey et al. 2001; Squire et al. 2008). 
The adrenal glands are two small organs with 4-5g of weight, located on the top of the kidneys 
with a pyramidal form, extending toward the hilum of each kidney. The arterial blood supply is done 
by branches from the aorta, the inferior phrenic artery and the renal artery (Kay et al. 2008). 
These organs are organized in two different structural and functional parts: the adrenal cortex and 
the adrenal medulla. The adrenal cortex secretes mainly mineralocorticoids (aldosterone), 
glucocorticoids (cortisol) and androgen. The adrenal medulla, through direct stimulation by 
acetylcholine from sympathetic nerves, secretes catecholamines - epinephrine (80%), norepinephrine 
(20%) and minimal amounts of dopamine (Kay et al. 2008). Catecholamines modulate stress response, 
metabolism and blood pressure (DeLellis 2004). 
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The adrenal medulla constitutes less than 20% of the adrenal gland and it’s composed by 
chromaffin cells. These are polygonal cells, organized in cords and with neural crest origin, which 
synthesize and secrete epinephrine and norepinephrine in response to stimulation of pre-ganglionic 
cholinergic sympathetic nerves. Thus, they are considered modified post-ganglionic sympathetic 
neurons and contain secretory granules for catecholamines. According to the hormone synthetized 
these cells can be divided in two types:  cells containing epinephrine (the majority of chromaffin cells) 
that stimulates glycogenolysis, lipolysis and inhibits insulin secretion; cells containing norepinephrine 
(minority of the chromaffin cells) that stimulates α- and β-adrenergic receptors in cells causing higher 
blood pressure, heart rate and cardiac contractility (Dudek 2000; Kuehnel 2003; Kay et al. 2008). They 
receive blood from the venules of the cortex rich in cortisol that in turn drain to medullary venules, or 
directly from medullary arterioles. The name “chromaffin” comes from the tumour tissue affinity for 
chromate salts, leading to characteristic staining (Nussey et al. 2001; Linos et al. 2005 ; Welander et 
al. 2011). 
 
The paraganglionic system has an origin in the neural crest tissue, during early gestation, 
becoming very similar in terms of histological features. This tissue comprises two parts: the adrenal 
medulla and the diffuse extra-adrenal paraganglia. Additionally, the extra-adrenal paraganglia is 
organized in sympathoadrenal and parasympathetic paraganglia: the sympathetic paraganglia 
comprises the axial regions of the trunk along the prevertebral and paravertebral sympathetic chains 
from the neck near the superior cervical ganglion to the abdomen and pelvis, and also the connective 
tissue within or near pelvic organs like bladder and prostate gland; the parasympathetic paraganglia is 
almost entirely restricted to the head and neck parasympathetic nerves and upper mediastinum, 
being the most common location the carotid body. The carotid body functions as detector of 
alterations in oxygen and carbon dioxide partial pressure in the arterial blood, as well as sensor of pH 
and temperature. Other locations of parasympathetic paraganglia include the jugulotympanic 
ganglion, along the glossopharyngeal and vagus nerves and more rarely the orbit, nasal cavity, 
paranasal sinuses, nasopharynx, larynx, trachea and thyroid (Nussey et al. 2001; DeLellis 2004; Linos 
et al. 2005 ; Welander et al. 2011). 
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Figure 1 – Anatomical structures of paraganglia (Welander et al. 2011). 
 
Tumours arising from adrenal medulla are termed pheochromocytomas, whereas tumours from 
extra-adrenal paraganglia are named extra-adrenal paragangliomas, or only paragangliomas, defined 
by the World Health Organization (Welander et al. 2011). 
Although PCC and PGL are indistinguishable at the cellular level, several differences are found 
concerning the anatomic distribution and secretory products (DeLellis 2004). 
 
EPIDEMIOLOGY OF PCC AND PGL 
PCC and PGL are rare tumours with an annual incidence of two to ten cases per million people. 
Although occurring in all ages, they are most frequent between 30 and 50 years, with a similar 
distribution between genders (DeLellis 2004). These tumours are often benign, but associated with 
high morbidity and mortality due to a mass effect and high levels of circulating catecholamines 
(Welander et al. 2011; Fishbein et al. 2012). 
In terms of relative incidence of the different tumour types, PCC is the most prevalent tumour, 
followed by sympathetic PGL and parasympathetic PGL (Fishbein et al. 2012). 
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In 2002 a graded score was created, in order to help predicting potential malignancy of PCC/PGL 
based in histological findings of the tumours (vascular density, amount of necrosis, among other 
features); nevertheless, it was considered unreliable due to variability (Welander et al. 2011). 
Nowadays, the WHO guidelines define malignant PCC/PGL as a metastatic lesion to sites where 
chromaffin tissue is not normally present (Fishbein et al. 2012). 
The presence of distant metastases, mainly in bone, liver and lung tissue occurs, approximately, in 
5-13% of PCC, 15-23% of sympathetic PGL and 2-20% of parasympathetic PGL (Bardella et al. 2011; 
Fishbein et al. 2012). 
 
SYMPTOMS  
PCC and sympathetic PGL have histological and functional similarities (Welander et al. 2011; 
Fishbein et al. 2012). A deregulation in synthesis and secretion of catecholamines by chromaffin cells 
of the paraganglionic tissue leads to large amounts of circulating hormones – epinephrine, 
norepinephrine, dopamine – at rates many times higher than normal (Welander et al. 2011). PGL of 
parasympathetic origin, in contrast, is a nonfunctional tumour, generally nonsecretory (DeLellis 2004; 
Welander et al. 2011). 
The excessive catecholamine secretion in PCC’s and sympathetic PGL’s can cause hypertension, 
severe cardiovascular and neurological manifestations such as seizures, shock, heart failure, cardiac 
arrhythmias and stroke and even death. The main symptoms include headache, palpitations, 
diaphoresis, pallor, anxiety, nausea, tremors, abdominal and chest pain, although some patients 
(10%) have minor or no symptoms (DeLellis 2004; Welander et al. 2011). These symptoms become 
worse and more frequent with tumour progression (Blake et al. 2011; Welander et al. 2011; Fishbein 
et al. 2012). 
PGL of parasympathetic origin presents as a slow-growing, painless cellular mass, frequently 
asymptomatic (Blake et al. 2011). Nevertheless, the compression of vital organs by the tumour mass 
can lead to the appearance of uncomfortable symptoms (DeLellis 2004; Welander et al. 2011). 
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GENETICS  
PCC and PGL are usually sporadic, but they frequently occur as part of several different hereditary 
tumour syndromes (Bardella et al. 2011). To date, ten genes have been identified as predisposing to 
the development of PCC and PGL, making these the tumours with the largest number of associated 
genes (Fishbein et al. 2012). 
Genetic screening in patients with PCC or PGL had not been considered until the year 2000, when 
only about 10% of these tumours were classified as hereditary cases as part of multiple tumour 
syndromes. Only recently the genetic screening for hereditary disease was recommended, since the 
frequency of germline mutations increased to about one third of all PCC and PGL cases (Fishbein et al. 
2012). 
The most studied genes are the succinate dehydrogenase (SDH) complex subunit genes that 
comprise SDHA, SDHB, SDHC and SDHD genes as well as the SDH complex cofactor SDHAF2. 
Moreover, recent susceptibility genes have been linked with PCC and PGL development - TMEM127 
and MAX (Iacobone et al. 2011; Jafri et al. 2012). Three additional PCC and PGL susceptibility genes 
are associated with well characterized familial syndromes - RET gene for multiple endocrine neoplasia 
type 2 (MEN2), VHL gene for von Hippel-Lindau disease (VHL) and NF1 gene for neurofibromatosis 
type 1 (NF1) (Fishbein et al. 2012). 
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Figure 2 – Signalling pathways for the ten genes associated with PCC/PGL’s development (Fishbein et al. 2012). 
 
SDH COMPLEX AND MITOCHONDRIA 
Mutations in any of the succinate dehydrogenase (SDH) complex genes that encode complex II, 
the simplest of the electron transport chain, cause familial PCC/PGL syndromes. The SDH enzyme is a 
highly conserved heterotetrameric protein that comprises four subunits - SDHA, SDHB, SDHC and 
SDHD. These four subunits are encoded by homonymous nuclear genes and imported to the 
mitochondria where they undergo modifications, folding and assembly (Fishbein et al. 2012). 
The mitochondrion is an organelle surrounded by a double-membrane - the inner and the outer 
mitochondrial membranes – separated by an intermembrane space and with an internal matrix. The 
inner membrane constitutes numerous folds – cristae – which extend to the matrix of the organelle. 
Each component plays a different function in the organelle with matrix and inner membrane as the 
most important compartments of mitochondria (Bardella et al. 2011; Welander et al. 2011; Fishbein 
et al. 2012). Typically, mammalian cells contain hundred mitochondria and liver cells more than a 
thousand (Cooper 2000; Alberts et al. 2002). 
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Mitochondria play a critical role in the generation of metabolic energy in eukaryotic cells. The 
main processes performed in mitochondria are the Krebs cycle, the β-oxidation pathway of fatty acid 
metabolism and oxidative phosphorylation. The aim of these pathways is the production of ATP, the 
useful energy for all the metabolic processes performed in the human body, as well as intermediate 
metabolites that can be used in anabolic metabolism (Metzler 2004). 
The breakdown of glucose and fatty acids by oxidative reactions allows the formation of metabolic 
energy. In the initial stage of glucose metabolism, named glycolysis, glucose is converted in pyruvate 
in the cytosol. This glycolysis product is then transported into the mitochondrial matrix where it 
suffers a series of oxidations termed as the Krebs cycle. Pyruvate is oxidized to acetyl CoA and 
consequently broken down to CO2 by specific enzymes located in the matrix of mitochondria. 
Concomitantly, NAD+ (nicotinamide adenine dinucleotide) and FAD (flavin adenine dinucleotide) are 
reduced to NADH and FADH2, respectively, and the high-energy electrons from these products are 
transferred to a series of carriers in the inner mitochondrial membrane in order to achieve the 
oxidative phosphorylation. The energy formed along the transfer reactions is then converted in 
potential energy to generate ATP (Cooper 2000; Metzler 2004). 
The electron transport chain has many components, particularly cytochromes a, a3, b, c and c1 as 
well as flavins, ubiquinone and nonheme iron. Furthermore, this pathway consists of five complexes 
that catalyze different reactions in the electron transport process: NADH-ubiquinone oxidoreductase 
(complex I), succinateubiquinone oxidoreductase (complex II), ubiquinolcytochrome c oxidoreductase 
(complex III), cytochrome c oxidase (complex IV) and ATP synthase (complex V) (Cooper 2000). 
All the complexes are linked by ubiquinone and cytochrome c, two soluble electron carriers 
(Metzler 2004). 
As previously mentioned, SDH comprises four genes. The gene SDHA encodes the flavin protein 
with 70kDa that binds FAD as cofactor in the catalytic core allowing the binding to succinate (Metzler 
2004). SDHB encodes the other part of the catalytic domain which also forms an interface with the 
membrane anchor. The protein encoded is an iron protein of 28 kDa that contains three iron-sulphur 
clusters (2Fe-2S, 3Fe-4S and 4Fe-4S) for electron transport from flavin to the final acceptor 
ubiquinone (Horsefield et al. 2006; Welander et al. 2011; Fishbein et al. 2012). 
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These two proteins, SDHA and SDHB, form a peripheral complex attached to the inner membrane 
of the mitochondria through two hydrophobic membrane proteins encoded by SDHC and SDHD genes 
(Horsefield et al. 2006; Welander et al. 2011; Fishbein et al. 2012). SDHC and SDHD proteins comprise 
three membrane helices, a histidine sidechain for binding a b-type cytochrome and two ubiquinone-
binding sites (Horsefield et al. 2006; Welander et al. 2011; Fishbein et al. 2012). 
The SDH mitochondrial enzyme complex is the only one involved both in the electron transport 
chain and in the Krebs cycle (Smeitink 2004; Horsefield et al. 2006). The main functions of SDH 
enzyme include catalyzing the oxidation of succinate to fumarate in the Krebs cycle and also 
transferring electrons to the terminal acceptor ubiquinone or coenzyme Q in the electron transport 
chain, reducing it to ubiquinol (Horsefield et al. 2006; Fishbein et al. 2012). 
Germline mutations in nuclear genes encoding SDH subunits linked for the first time a genetic 
mitochondrial defect and tumour development, in this case PCC and PGL (Horsefield et al. 2006; 
Welander et al. 2011; Fishbein et al. 2012). 
The initial linkage analysis studies identified three PGL susceptibility loci on chromosomes 11 and 
1, which were categorized as “paraganglioma locus 1” (PGL1) on 11q23, “paraganglioma locus 2” on 
11q13.1 and “paraganglioma locus 3” on 1q21 (Bardella et al. 2011). 
In 2000, gene mapping studies allowed the identification of SDHD as the PGL1 gene; patients with 
familial PGL’s were found to harbour germline loss-of-function SDHD mutations, giving rise to the link 
between SDH and neuroendocrine tumours (Bardella et al. 2011). SDHD mutations were thereafter 
discovered in familial and apparently sporadic PCC/PGL’s (Bardella et al. 2011; Welander et al. 2011). 
Soon after, SDHB germline mutations (PGL4) were identified in both familial PCC’s and PGL’s, followed 
by SDHC mutations (PGL3) in PGL (Welander et al. 2011). In contrast, mutations in the SDHA gene 
were only identified in 2010, when a patient with PGL and another with PCC were found to harbour a 
germline SDHA mutation (Bardella et al. 2011; Welander et al. 2011). 
In 2009, two genes - SDHAF1 and SDHAF2 – which encode succinate dehydrogenase complex 
assembly factors 1 and 2 were discovered and SDHAF2 gene mutations (PGL2) were associated with 
PGL’s but not with PCC’s patients (Bardella et al. 2011; Welander et al. 2011). These two factors are 
involved in the assembly of the SDH complex (Karasek et al. 2010; Welander et al. 2011). 
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SDH genes function as tumour suppressors with alterations such as missense, nonsense, 
frameshift and splice-site mutations (Welander et al. 2011). The genetic variants in SDH genes that 
predispose to PCC/PGL are germline heterozygous mutations with LOH of the non-mutated allele in 
the tumour tissue that leads to suppression of SDH enzyme activity and an absence of protein 
expression, resulting in neoplastic transformation (Welander et al. 2011). The most commonly 
mutated genes are SDHB and SDHD (Bardella et al. 2011; Welander et al. 2011). 
The incidence of PCC/PGL syndrome is estimated to be between 1/50 000 and 1/20 000 (Welander 
et al. 2011). It is estimated that, by the age of 35, 38% to 60% of individuals with mutations in SDHD, 
SDHB and SDHC genes will develop PCC/PGL’s (Welander et al. 2011). Patients with inherited 
susceptibility to PCC/PGL’s present more frequently aggressive tumours and increased risk of 
metastasis and mortality (Bardella et al. 2011). 
Family history of PCC/PGL, multifocal disease, younger age at onset and malignant tumours are 
insufficient clinical indicators for correct diagnosis of the syndrome. Besides, the detection of 
inherited PCC/PGL’s is important for patients with this syndrome, as well as for their family members, 
since they have increased risk of developing multiple and malignant neoplasms (Nederveen et al. 
2009). 
Mutation analysis of SDHB, SDHC and SDHD has been indicated to diagnose PCC/PGL’s in all cases 
where there are no clear clinical or family signs for the syndrome. However, mutation analysis among 
PCC/PGL’s patients frequently identify more cases without mutations than SDH-mutation carriers, 
making genetic screening approach a financially demanding and labour-intensive procedure 
(Nederveen et al. 2009). 
Additionally, several reports have shown that a germline mutation in a SDH gene induces a 
complete absence of SDH enzyme activity in the tumour, irrespectively of the mutated SDH subunit - 
anchorage (SDHC and SDHD) or catalytic (SDHB) subunits -, suggesting a conformational change or a 
destabilization of the complex II (Gimenez-Roqueplo et al. 2001; Gimenez-Roqueplo et al. 2002; 
Dekker et al. 2003; Gill et al. 2010). In fact, there is an almost perfect correlation between the 
presence of a germline SDHB, SDHC or SDHD mutation and loss of SDHB expression on the tumour 
tissue, making SDHB immunohistochemistry the optimal method for discriminating between SDH-
mutated and SDH-wild-type PCC/PGL’s (Nederveen et al. 2009). 
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SDHB immunohistochemistry is highly sensitive and specific for the presence of an SDH mutation 
and is technically and financially reasonable, in particular in the absence of familial or clinical 
indications of a specific form of inherited PCC/PGL. Thus, genetic screening should only be performed 
when tumours show negative immunohistochemical SDHB expression. Obviously, this approach can 
only be performed whenever tumour tissue is available for study (Nederveen et al. 2009; Gill et al. 
2010). 
Additionally, SDHA-mutant tumours can be detected when the tumours are negative for SDHB and 
SDHA immunostaining, while SDHB, SDHC and SDHD-mutated tumours showed loss of SDHB 
expression and positive SDHA (Burnichon et al. 2010). 
 
SDHD GENE 
The SDHD gene is located on chromosome 11q23, has 4 exons and encodes a 103 amino acid 
protein. The SDHD protein is a small anchoring subunit implicated in electron transfer from iron 
sulphur clusters within SDHB, through an ubiquinone binding site (Fishbein et al. 2012). SDHD 
together with SDHC, form the anchoring structure of SDH in the mitochondrial complex II (Bardella et 
al. 2011). 
PGL1 syndrome characterized by mutations in SDHD gene, has an autosomal dominant inheritance 
with a parent of origin effect. It is though that the gene is maternally imprinted, since the disease 
susceptibility occurs only when the mutation is inherited from the father, whereas no disease is 
observed when the mutation in inherited from the mother; however, the reasons behind this mode 
of inheritance are not yet fully understood. There is a rare case of a patient with jugulo-tympanic PGL 
showing a maternally transmitted SDHD mutation, but there is no available histological and molecular 
study of the tumour tissue to give more important information (Pigny et al. 2008; Bardella et al. 
2011). 
SDHD mutations can be missense, nonsense, frameshift and rarely splice-site (Benn et al. 2006). 
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Founder mutations have been discovered in different populations: American (p.Pro81Leu); 
Chinese (p.Met1Ile); Dutch (p.Asp92Tyr, p.Leu95Pro, p.Leu139Pro); Spanish (p.Trp43X); Italian 
(p.Gln109X) and Austrian (large Alu-mediated deletion – 4944 bp) (Bardella et al. 2011). 
PGL1 appears by the age of 35, with a penetrance of about 86% by the age of 50 years. The 
parasympathetic PGL (often multifocal) is the most prevalent presentation (84%), followed by PCC 
(24%) and sympathetic PGL (22%). The risk of malignancy reaches only 5% (Welander et al. 2011; 
Fishbein et al. 2012). 
 
SDHAF2 GENE 
SDHAF2 is located on chromosome 11q12.2 and encodes a 167 amino acid protein which is 
involved in the incorporation of FAD cofactor in the subunit A of the succinate dehydrogenase 
complex, being essential for the SDH enzyme activity (Bardella et al. 2011; Fishbein et al. 2012; Jafri et 
al. 2012). Loss of SDHAF2 causes loss of SDHA function, decreasing the stability of SDH enzyme 
complex (Karasek et al. 2010). 
PGL2 is associated with mutations in SDHAF2 gene and is inherited in an autosomal dominant 
manner. Like PGL1, this syndrome is associated with a parent of origin effect, since disease 
susceptibility occurs only with paternal transmission of the mutation and the absence of disease 
occurs when mutation is maternally inherited (Welander et al. 2011). 
The few cases reported to date with PGL2, describes early-onset tumours with the same founder 
mutation (Welander et al. 2011; Fishbein et al. 2012). 
In a Dutch and Spanish family a germline loss-of-function mutation was identified in a conserved 
region of SDHAF2 gene (p.Gly78Arg), resulting in decreasing flavination of SDHA subunits. Through 
the haplotype analysis of the two families it was discarded a common genetic origin between them, 
revealing that this mutation is a recurrent variant affecting the function of SDHAF2 protein (Baars et 
al. 1981; Bayley et al. 2010). 
No other additional studies found mutations in SDHAF2 gene, demonstrating that they are rare 
events (Bardella et al. 2011). 
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The mean age of PCC/PGL appearance is 33 years with a 100% penetrance by the age of 45 years 
(Welander et al. 2011; Fishbein et al. 2012). 91% of affected individuals have multifocal 
parasympathetic PGL’s, with no malignancy associated (Fishbein et al. 2012). No cases of PCC’s have 
been described in PGL2 syndrome (Karasek et al. 2010). 
 
SDHC GENE 
SDHC gene is located on chromosome 1q23.3, has 6 exons and encodes a 140 amino acid protein 
that consists of the large subunit cybL of cytochrome b in the mitochondrial complex II (Bardella et al. 
2011; Fishbein et al. 2012). 
Mutations in SDHC gene causes PGL3 syndrome with an autosomal dominant transmission 
(Fishbein et al. 2012). In contrast to PGL1 and PGL2 this familial form is not characterized by parent-
of-origin effect since the disease occurs upon maternal and paternal transmission of the mutation 
(Bardella et al. 2011). 
Mutations in this gene are less common than in SDHD and SDHB, occurring in 0 to 7% of PCC/PGL 
patients (Fishbein et al. 2012). 
It was identified an Alu-mediated genomic deletion of 8.4kb involving exon 6 in a family and in an 
unrelated sporadic case with a common haplotype, supporting a common ancestral origin (Bardella et 
al. 2011). 
The mean age of PCC/PGL onset is 38 years, ranging from 17 to 70 years old (Fishbein et al. 2012). 
Like in PGL1 and 2, parasympathetic PGL is the mainly tumour that develops in SDHC mutated 
patients (93%), with rare development of sympathetic PGL (7%) and more rarely PCC (Welander et al. 
2011; Fishbein et al. 2012). The risk of malignancy is very low (Fishbein et al. 2012). 
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SDHB GENE 
SDHB is located on chromosome 1p35-p36, has 8 exons and encodes a 280 amino acid protein that 
constitutes the iron sulphur subunit of the succinate dehydrogenase complex (Fishbein et al. 2012). 
This protein in combination with SDHA constitutes the catalytic domain of SDH (Bardella et al. 2011). 
PGL4 syndrome is caused by SDHB mutations with an autosomal dominant inheritance and, like 
PGL3, both paternal and maternal disease transmission is observed (Bardella et al. 2011; Fishbein et 
al. 2012). 
Point mutations, small insertions and deletions or duplications of the SDHB gene loci are examples 
of mutations that are associated with higher morbidity and mortality than mutations in other SDH 
genes (Welander et al. 2011; Fishbein et al. 2012). 
Recently, SDHB missense mutations were associated with an increased risk of parasympathetic 
PGL when compared to truncating mutations. In addition, large deletions were also discovered in 
familial and apparently sporadic PCC/PGL cases that show phenotypes and penetrance similar to 
those of patients with point mutations. Large germline founder deletions were identified in 
individuals from Netherlands (7905 bp deletion in exon 3) and Spain (16 kb deletion involving exon 1). 
Two other mutations, p.P56delYfsX5 in Spanish population and IVS1 + 1 G>T in the Scottish 
population were also identified as having a possible founder effect (Bardella et al. 2011). 
Most of the tumours associated with SDHB mutations are sympathetic PGL’s in abdomen and 
pelvis (74%), but PCC’s (25%) and parasympathetic PGL’s (24%) are also observed (Fishbein et al. 
2012). Tumours associated with SDHB mutations are often large, mainly solitary and with a strong 
tendency for metastasis (Karasek et al. 2010). 
The mean age of PGL4 onset is about 33 years with a penetrance of 80-100% by the age of 70 
(Welander et al. 2011; Fishbein et al. 2012). The risk of malignancy associated is substantial, ranging 
from 31 to 71%. This wide range of malignancy risk is associated with long time to develop 
metastases, which is thought to be up to 20 years after primary tumour diagnosis (Fishbein et al. 
2012). Because of the high potential of malignancy and poor prognosis, SDHB carriers should start 
screening of PGL/PCC at the age of 10 (Bardella et al. 2011). 
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Mutations in SDHB are associated with the development of other neoplasias such as 
gastrointestinal stromal tumours (GIST), breast and papillary thyroid carcinoma (PTC), neuroblastoma 
and renal cell carcinoma (clear-cell and papillary RCC) (Karasek et al. 2010; Fishbein et al. 2012). 
PCC/PGL’s related with SDHB and SDHD have a biochemical phenotype that allows to distinguish 
them from tumours associated with VHL, RET or NF1 mutations. PGL1 and PGL4 patients have an 
increased level of methoxytyramine which indicates dopamine hypersecretion that can occur alone or 
in association with norepinephrine hypersecretion (SDHB-related tumours) (Karasek et al. 2010). 
 
SDHA GENE 
SDHA gene is located on chromosome 5p15 and encodes a 621 amino acid protein – flavoprotein – 
which is the major catalytic subunit in the succinate dehydrogenase complex, comprising a prosthetic 
group covalently attached to FAD (Bardella et al. 2011; Fishbein et al. 2012). This subunit binds 
enzyme substrates - succinate and fumarate – as well as physiological regulators – oxaloacetate and 
ATP (Bardella et al. 2011). 
Recently, Burnichon et al. discovered, in a patient with abdominal PGL, the first heterozygous 
germline missense mutation (p.Arg589Trp) associated with somatic LOH at the SDHA locus within the 
tumour (Burnichon et al. 2010). Subsequently, the same group reported a series demonstrating that 
SDHA mutations represent 3% of germline mutations in apparently sporadic PCC/PGL (Korpershoek et 
al. 2011). So far, only six patients with PCC/PGL’s were identified with SDHA mutations, three with 
sympathetic PGL, two with parasympathetic PGL and one of them with PCC (Welander et al. 2011; 
Korpershoek et al. 2012). 
Interestingly, SDHA germline homozygous mutations that cause loss or reduced enzymatic activity 
are associated with other diseases like Leigh’s syndrome (encephalopathy), a neurodegenerative 
disorder with an early onset and autosomal recessively inheritance, as well as optic atrophy, ataxia 
and myopathy, late-onset disorders (Bardella et al. 2011; Fishbein et al. 2012; Jafri et al. 2012). 
As the number of mutations in SDHA gene is very low, the prevalence of mutations and risk of 
malignancy are not yet determined (Fishbein et al. 2012). 
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The mean age of SDHA related PCC/PGL’s development is about 40 years old (Fishbein et al. 2012). 
 
TMEM127 GENE 
TMEM127 - transmembrane protein 127 - is located on chromosome 2q11.2, has 4 exons (the first 
is non-coding) and encodes a 238 amino acid protein. TMEM127 protein comprises three 
transmembrane domains and co-localizes with the early endosome in the cell, being involved in the 
mTORC1 (mechanistic target of rapamycin complex 1) signalling pathway (Fishbein et al. 2012). 
In 2005, TMEM127 was recognized as a PCC/PGL’s susceptibility gene after the identification of 
germline loss-of-function mutations, particularly missense and nonsense, in patients with PGL and 
PCC. It functions as a tumour suppressor gene with presence of LOH identified in all tumours carrying 
a mutation (Dahia et al. 2005). 
Mutations in this gene have a frequency of about 2% and confer tumour susceptibility in an 
autosomal dominant pattern (Fishbein et al. 2012; Jafri et al. 2012). 
Most of the tumours associated with TMEM127 mutations are PCC’s (96%) with 39% being 
bilateral PCC’s, followed by PGL’s (9%) with an equal frequency between sympathetic and 
parasympathetic PGL’s (Welander et al. 2011). The mean age of onset is 45 years and the malignancy 
risk is very low (Fishbein et al. 2012). 
Other tumours are associated with mutations in TMEM127 gene, such as medullary thyroid 
carcinoma, breast cancer and myelodysplasia, but the causal link is still under debate (Welander et al. 
2011). 
TMEM127 is particularly localized in multiple endomembrane organelles such as endosomes, Golgi 
apparatus and lysosomes and is associated with endosomal pools, participating in protein trafficking 
between the plasma membrane and these organelles. mTOR components are also confined to 
endosomal and vacuolar compartments (Jiang et al. 2011). 
The function of TMEM127 is not well established, but it is thought that it functions as a negative 
regulator of mTOR (Welander et al. 2011). 
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Loss of function TMEM127 mutations leads to increased phosphorylation of mTORC1 targets such 
as 4EBP1 (eukaryotic translation initiation factor 4E binding protein 1) and S6K (ribosomal protein S6 
kinase), as well as increased cell size and proliferation in numerous cell lines. In vivo studies showed 
the same hyperphosphorylation of mTORC1 targets in patients with TMEM127 mutations and no 
changes in phosphorylation of mTORC2 targets, suggesting that TMEM127 is a negative regulator of 
mTORC1 but not mTORC2. Despite the aforementioned findings, the precise role of TMEM127 in 
mTOR pathway is still to be uncovered. In fact, TMEM127 is considered a member of a newly 
“oncogenic endomembrane network”, a new regulatory system in cancer whose functions are still 
unknown (Jiang et al. 2011). 
 
MAX GENE 
MAX gene or myc-associated factor X is located on chromosome 14q23, has five exons and 
encodes a transcription factor with 160 amino acids, being a member of the basic helix-loop-helix 
leucine zipper family that comprises the MYC, MAX and MAD proteins (Welander et al. 2011; Fishbein 
et al. 2012; Jafri et al. 2012). 
The MYC family proteins, c-MYC, n-MYC and l-MYC are oncoproteins associated with cell 
proliferation, differentiation and neoplasia (Ecevit et al. 2010). 
MAX is similar to MYC, but lacks the transactivation domain (Ecevit et al. 2010). All known 
oncogene functions of MYC require that MAX heterodimerizes with MYC in the MYC-MAX-MAD 
network, resulting in transcription activation of target genes through the trans-activating domain of 
MYC which is associated with cellular proliferation, differentiation and apoptosis. On the other hand, 
when MAX heterodimerizes with MAD, the transcription repression of the same target genes occurs, 
a function that antagonizes MYC-MAX heterodimer (Ecevit et al. 2010; Welander et al. 2011; Fishbein 
et al. 2012; Jafri et al. 2012). Therefore, the binding of these similar transcription factor dimers to the 
E-box determines the cell destiny: division and proliferation with MYC-MAX dimer or differentiation 
and quiescence with MAD-MAX dimer (Ecevit et al. 2010). 
MAX was identified as a susceptibility gene for PCC/PGL by Comino-Méndez et al. using whole 
exome sequencing on germline DNA (Comino-Méndez et al. 2011). The mutations identified were 
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inactivating mutations particularly missense, nonsense and splice site; the concomitant LOH and loss 
of MAX expression in the tumour tissue are consistent with tumour suppressor function (Welander et 
al. 2011; Jafri et al. 2012). 
Similarly to what happens in PGL1 and PGL2 syndromes, MAX mutations have a parent-of-origin 
effect since paternal transmission of the gene is necessary for tumour development (Jafri et al. 2012). 
Patients with MAX mutations exhibit bilateral PCC’s in 67%; no studies on large series of PGL’s 
were performed so far. The mean age at presentation is about 32 years and the malignancy risk is 
high (Welander et al. 2011). 
 
OTHER GENES 
RET GENE 
RET - rearranged during Transfection - gene was discovered in 1985 by transfection of NIH 3T3 
cells with human lymphoma DNA (Welander et al. 2011). RET is located on chromosome 10q11.2, has 
21 exons and encodes an 860 amino acid transmembrane receptor tyrosine kinase whose main 
function is the regulation of cell proliferation and apoptosis (Fishbein et al. 2012). When a specific 
ligand, particularly the members of the glial cell line-derived neurotropic factor family (GDNF), bind to 
RET receptor, a dimerization is induced and triggers phosphorylation of specific tyrosine residues and 
activation of multiple intracellular pathways (Karasek et al. 2010; Welander et al. 2011; Fishbein et al. 
2012). 
The RET protein acts in the development of the kidney and sympathetic, parasympathetic and 
enteric nervous system, thus it is mostly expressed in urogenital and neural crest precursor cells 
(Welander et al. 2011). 
Germline gain of function RET mutations predispose to multiple endocrine neoplasia type 2 
(MEN2), which is an autosomal dominant syndrome with a prevalence of 1/40 000 individuals 
(Karasek et al. 2010; Welander et al. 2011). 
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Over 50 different missense mutations have been identified in MEN2 families and can be found in 
exon 10 codons 609, 611, 618, 620 and exon 11 specifically in codons 630, 634, all of them resulting in 
cysteine substitution; exon 13 codons 768 (Glu→Asp), 790 (Leu→Phe) and 791 (Tyr→Phe); exon 14 
codon 804 (Val→Leu); exon 15 codons 883 (Ala→Thr) and 891 (Ser→Ala) and exon 16 codon 918 
(Met→Thr). PCC/PGL development is associated with codons 634 and 918 mutations in approximately 
50% of patients, with exon 10 mutations in up to 20% patients, and rarely with mutations in exons 13 
to 15 (Benn et al. 2006; Quayle et al. 2007; Raue et al. 2010; Welander et al. 2011). 
PCC/PGL’s related with MEN2 overexpress phenylethanolamine N-methyltransferase, an enzyme 
that converts norepinephrine to epinephrine. Consequently, the levels of epinephrine are increased, 
resulting in PCC symptoms – anxiety, headaches, and palpitations. Another feature of this familial 
syndrome is the presence of increased amounts of metanephrine, a metabolite of epinephrine, in 
plasma and urine, making possible a distinguishable pattern from patients with VHL and SDHx 
mutations (Karasek et al. 2010). 
MEN2 can be divided into three subgroups:  
 MEN2A (55% of all cases): 95% of the patients have medullary thyroid carcinoma 
(MTC), 50% have PCC and 15-30% have hyperparathyroidism caused by parathyroid 
hyperplasia or adenoma; the majority of patients have a mutation in codon 634 in exon 11 of 
RET (p.Cys634Arg or p.Cys634Tyr) (Karasek et al. 2010; Welander et al. 2011; Fishbein et al. 
2012; Jafri et al. 2012). 
 MEN2B (5-10% of all cases): 100% of the cases have MTC, 50% have PCC, marfanoid 
habitus and multiple mucosal ganglioneuromas; it is the most aggressive form of MTC with 
higher morbidity and mortality and earlier onset; a single missense mutation in codon 918 in 
exon 16 (p.Met918Thr) is the principal mutation (Karasek et al. 2010; Welander et al. 2011; 
Fishbein et al. 2012; Jafri et al. 2012). 
 Familial medullary thyroid carcinoma (35-40% of all cases): patients have only MTC, 
often less aggressive; mutations in the codons 768, 790, 804 and 891 are associated with only 
MTC susceptibility (Karasek et al. 2010; Welander et al. 2011; Fishbein et al. 2012). 
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RET mutations predispose to PCC that often presents as recurrent, bilateral (50% of patients) and 
with low risk of malignancy (5%); in contrast, PGL’s are very rare in MEN2 syndrome. The age of onset 
of MEN2 related PCC is commonly between the ages of 30 and 40 years (Karasek et al. 2010; 
Welander et al. 2011). 
 
VHL GENE 
VHL tumour suppressor gene is located on chromosome 3p25-26 and has 3 exons. More than 300 
mutations have been identified such as missense, nonsense, deletions and insertions (indels) that 
cause the Von Hippel-Lindau syndrome which is characterized by the development of both benign 
and malignant tumours in numerous organs. These are heterozygous germline mutations often 
associated with somatic loss of heterozygosity (LOH) of the wild-type allele in the tumour tissue (Benn 
et al. 2006; Karasek et al. 2010; Welander et al. 2011). About 20% of families have de novo mutations 
(Karasek et al. 2010). 
VHL protein function is to regulate the hypoxia inducible factor-1 alpha (HIF-1α) activity in blood 
vessel formation (Karasek et al. 2010). VHL protein has E3 ubiquitin ligase activity, which ubiquitinates 
HIF-1α that consequently undergoes proteasomal degradation, under normoxic conditions (Welander 
et al. 2011; Fishbein et al. 2012). In hypoxic conditions or when there is a mutation in VHL, HIF-1α is 
no longer degraded, being able to target the transcription of hypoxia inducible genes after 
complexing with HIF-1β and other proteins (Fishbein et al. 2012). 
Von Hippel-Lindau (VHL) is an autosomal dominant syndrome with a prevalence of 1/36 000 
individuals that can be divided into two types (Karasek et al. 2010): 
 VHL type 1: it is the most common form, without predisposition to develop PCC and 
associated with clear-cell renal carcinomas, retinal angiomas, central nervous system 
hemangioblastomas (brain, spinal cord and retina), islet tumours of the pancreas, 
endolymphatic sac tumours, cysts and cystadenomas (kidney, pancreas, epididymis and broad 
ligament); the most frequent mutations are truncating mutations or exon deletions (Karasek 
et al. 2010; Fishbein et al. 2012). 
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 VHL type 2: it is associated with PCC development and associated with missense 
mutations; the tumour spectrum of VHL type 2 depends on the location of the mutation 
(Karasek et al. 2010; Fishbein et al. 2012). This type can be divided in three subtypes:  
o VHL type 2A: without renal carcinoma and less predisposition to VHL type 1 
tumours (Karasek et al. 2010). 
o VHL type 2B: includes all VHL type 1 tumours (Karasek et al. 2010). 
o VHL type 2C: only PCC development (Karasek et al. 2010). 
 
Considering all subtypes of VHL, PCC/PGL development occurs in 10-26% of patients, with PCC’s as 
the most commonly form of catecholamine producing tumours (90%), although sympathetic and 
parasympathetic PGL tumours have been identified in rare occasions (19%) (Karasek et al. 2010; 
Welander et al. 2011). PCC presents as bilateral in more than 50% of the cases and is less malignant 
than sporadic PCC (<5% of patients) with a mean age of presentation of 30 years (Karasek et al. 2010). 
In families with PCC/PGL, missense mutations affecting the surface of the folded protein are more 
frequent than those affecting the deeper protein core or the ones that disrupt the interaction 
between VHL and HIF (associated with clear-cell renal carcinoma) (Welander et al. 2011; Fishbein et 
al. 2012). 
VHL patients present increased plasma and urinary levels of normetanephrine, which occurs due 
to low expression of pehnylethanolamine-N-methyltransferase with a consequently decreased 
production of epinephrine and increased production of norepinephrine (Karasek et al. 2010). VHL-
associated PCC/PGL’s are frequently asymptomatic, comparing to sporadic PCC/PGL’s (Jafri et al. 
2012). 
 
NF1 GENE 
NF1 gene was discovered in 1990 and is a tumour suppressor gene with over 60 exons, located on 
chromosome 17q11.2 that encodes a 2818 amino acids protein, named neurofibromin. This protein is 
particularly expressed in the nervous system and its main function is the GTPase activity to convert 
Ras into its inactive form, thereby inhibiting Ras/Raf/MAPK signalling pathway, as well as 
PI3K/AKT/mTOR pathway (Welander et al. 2011; Fishbein et al. 2012). When a NF1 mutation is 
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present, the mutant protein does not inactivate Ras, which becomes constitutively activated to 
trigger the subsequent oncogenic downstream pathways – MAPK, PI3K and mTOR (Fishbein et al. 
2012). 
Neurofibromatosis type 1 (NF1), also termed von recklinghausen’s disease is an autosomal 
dominant genetic disorder with an incidence of 1/3000 persons (Fishbein et al. 2012; Jafri et al. 2012). 
The alterations in NF1 gene comprise inactivating mutations such as missense, nonsense, splice-
site mutations and indels (Welander et al. 2011). 
Thirty to 50% of NF1 patients have mainly de novo mutations that can give rise to a mosaic 
phenotype (Welander et al. 2011; Fishbein et al. 2012). There is no hot spot in this large gene making 
it difficult to perform a genetic screening of the disease (Fishbein et al. 2012). As such, the diagnosis is 
based on clinical criteria that consist in having at least two features of the following ones (Karasek et 
al. 2010; Fishbein et al. 2012): 
 two or more cutaneous neurofibromas or a single plexiform neurofibroma; 
 two or more Lisch nodules (benign iris hamartomas); 
 six or more café-au-lait macules with specific size depending on age; 
 inguinal or axillary freckling; 
 at least one optic nerve glioma; 
 dysplasia of the long bones or pseudoarthrosis; 
 first-degree relative with NF1. 
 
Several tumours have been identified with high frequencies in NF1 patients, such as medullary 
thyroid carcinoma, parathyroid tumours, carcinoid tumours of the duodenal wall, peripheral nerve 
sheath tumours and leukemia (mainly chronic myeloid leukemia) (Karasek et al. 2010; Fishbein et al. 
2012). 
PCC/PGL occurs in NF1 syndromes with an estimated rate of 0-6% (up to 13% at autopsy) and 20-
50% in NF1 patients with hypertension (Karasek et al. 2010; Welander et al. 2011). Most of them are 
unilateral PCC’s (95%) and rarely bilaterally PCC’s (14%) or sympathetic PGL’s (6%) (Welander et al. 
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2011). The potential malignancy is around 12%. The mean age at presentation of PCC is 42 years 
(Karasek et al. 2010; Welander et al. 2011; Fishbein et al. 2012). 
The main alterations occurring in PCC’s associated with NF1 patients comprise changes in both 
alleles including one germline mutation and one acquired mutation or LOH of the wild-type allele 
(Welander et al. 2011). 
PCC related with NF1 syndrome has overproduction of epinephrine that causes an increase of 
metanephrine in the plasma and urinary levels (Karasek et al. 2010). 
 
OTHER SYNDROMES WITH RELATED PCC/PGL 
CARNEY’S TRIAD SYNDROME 
Carney’s Triad is a disorder that comprises PCC/PGL’s, GIST’s and pulmonary chondromas. This 
syndrome affects young women with a mean age of presentation of 21 years. Most of the patients 
with this disease have only two of the three tumours, mainly GIST and pulmonary chondroma; about 
20% have the all three tumour types of the triad (Welander et al. 2011). 
So far, no mutations in genes involved in familial PGL’s (SDHA, SDHB, SDHC, SDHD) or GIST (KIT and 
PDGFRA) were associated with Carney’s Triad syndrome (Welander et al. 2011). 
PGL’s appear in 92% of Carney’s Triad patients, both sympathetic and parasympathetic, and PCC’s 
are present in 16%. The mean age at presentation of PCC/PGL’s in this syndrome is 28 years and 
metastasis occurs in about 11% of patients (Welander et al. 2011). 
 
CARNEY-STRATAKIS SYNDROME 
Carney-Stratakis or Carney’s Dyad includes two types of tumours: PCC/PGL’s and GIST’s. It is 
transmitted by an autosomal dominant manner with incomplete penetrance. The mean age at 
presentation of the syndrome is 23 years with similar incidence in men and women. Most of the 
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patients display only PGL/PCC’s (58%), followed by patients with both tumours (33%) and a minority 
with only GIST (8%) (Welander et al. 2011). 
In contrast to Carney triad, the Carney dyad patients carry germline mutations in SDHB, SDHC or 
SDHD genes (Welander et al. 2011). 
In this syndrome, PGL’s appear in almost all the patients with only 9% frequency for PCC’s. The 
mean age at presentation is 33 years and with no malignancy associated (Welander et al. 2011). 
 
SPORADIC PCC/PGL’S 
The majority of PCC/PGL’s cases present as sporadic cases, without known familial history. 
Nevertheless, inherited mutations are present in 11 to 24% of patients with negative familial history 
of disease (Welander et al. 2011). 
Patients with apparently sporadic tumours have an older onset with a mean age at presentation of 
48 years and lower frequency of multiple tumours comparing to those with familial history (Welander 
et al. 2011). 
The majority of sporadic cases are PCC’s, 73%, with only 20% of parasympathetic PGL’s, 9% of 
sympathetic PGL’s and 6% of bilateral PCC’s; the rate of malignant disease is low (9%) in these 
presentations (Welander et al. 2011). 
 
GENETIC TESTING APPROACHES 
Considering the large number of genes involved in PCC/PGL, it is important to establish criteria to 
manage the genetic screening. The probability of detecting a mutation in an individual case includes 
the following clinical features (Jafri et al. 2012): 
 a personal or family history that indicates a syndromic cause, for example MTC in 
MEN2 syndromes or hemangioblastoma in VHL syndrome; 
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 a positive family history for PCC; 
 multiple primary PCC’s; 
 malignancy; 
 extra-adrenal location; 
 young age at diagnosis. 
 
Therefore, the personal history, family history and clinical examination are the major criteria for 
assessment of an appropriate germline mutation. In case of having a family history or evidence of 
specific features of each familial syndrome, targeted genetic testing should be done. Predictive 
testing allows the identification of asymptomatic patients who are at risk for disease development, 
which consequently will help in biochemical and radiologic screening, reducing morbidity and 
mortality (Karasek et al. 2010). 
Patients with a positive familial history have 90% probability of having a specific gene mutation. 
Germline mutations in non-syndromic patients is estimated about 18-19%, but in the case of multiple 
or recurrent PCC/PGL’s, the frequency is about 39% (Karasek et al. 2010). 
Sporadic PCC/PGL’s without familial history or other symptoms of familial syndromes show genetic 
mutations in 18-19% of the cases. In multiple or recurrent PCC/PGL’s the frequency of mutations is 
about 39% (Karasek et al. 2010). 
In patients with early onset, bilateral, multifocal, extra-adrenal, tumours with recurrent or 
malignant disease, a germline mutation is likely to be present (Karasek et al. 2010). 
NF1 is identified by a careful physical examination, discarding a genetic testing for NF1 gene (Jafri 
et al. 2012). 
For the other genes, a genetic testing diagram can be followed in the diagnosis (Figure 3). 
  
INTRODUCTION 
38 
 
 
 
 
If the patient has a positive family history, syndromic lesions or both, the appropriate specific gene 
test should be performed. In non-syndromic patients or without family history, immunohistochemical 
analysis for SDHB should be done to identify SDH-related tumours in negative SDHB staining. If it is 
the case, SDH genetic analysis is the second step to find mutations that lead to loss of SDHB 
expression. If the immunohistochemistry shows positive SDHB expression, other genes should be 
tested, such as the MAX and TMEM127 genes, according to type of tumour (Karasek et al. 2010). 
Furthermore, since MAX mutations demonstrated loss of MAX expression in the tumour tissue, 
immunohistochemistry for MAX can be considered as a potential marker for MAX germline mutations 
(Jafri et al. 2012). 
Figure 3 – Diagram of the genetic testing protocol as an example of diagnostic approach (Welander et al. 2011). 
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It is currently known that a significant proportion of PCC/PGL’s is due to germline mutations in ten 
susceptibility genes – SDHA, SDHB, SDHC, SDHD, SDHAF2, MAX, VHL, TMEM127, RET and NF1. The 
main aim of this work was to perform a molecular analysis of blood and tumour samples in patients 
with PCC/PGL’s, in order to establish the molecular basis of the disease. For that matter, we have 
looked for mutations in SDH, SDHAF2, MAX and TMEM127 genes in patients without evidence of 
syndromic (MEN2, VHL or NF1) disease; whenever a patient demonstrated signs of such syndromes, 
the causative gene was studied. Once identified the genetic alterations, we looked for genotype-
phenotype correlations in an attempt to progress in the clinical management of PCC/PGL patients. 
From the studies reported so far, the prevalence of mutations in the aforementioned ten genes is 
associated with the population under study. Here, we had access to Polish and Portuguese 
populations with PCC/PGL’s, allowing a similar study to those performed for other populations. This 
thesis is divided taking into account these two different populations: the first part concerning a Polish 
population with only PCC’s; the second part regarding Portuguese population with PCC or PGL. 
 
PART I 
The first part of the thesis comprised a series of 61 samples of paraffin embedded tissue from 
Polish PCC patients. This series had already been clinically characterized and we had contact with a 
pathologist from Poland responsible for these cases, which provided us all the clinico-pathological 
information collected from the patients. 
Thus, based on previous reports about PCC/PGL’s, we decided to perform an expression study for 
SDH protein followed by a genetic screening for SDHB, SDHC, SDHD, SDHAF2, TMEM127 and MAX.  
More specifically, an immunohistochemical study in order to find tumours with loss of SDH 
enzyme expression was performed; the samples with loss of expression were screened for mutations 
in SDH (except SDHA) and SDHAF2 genes to find the pathogenic mutation responsible for PCC 
susceptibility. In those tumours with presence of SDHB expression (indicating absence of SDH 
mutations), genetic characterization for MAX and TMEM127 genes was accomplished. Finally, 
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genotype-phenotype correlations were accomplished in order to take some conclusions about this 
population of PCC’s. 
PART II 
Concomitantly, in the second part of this thesis, 12 blood samples from Portuguese PGL/PCC 
patients were analysed. In this series no tumour tissue was available to perform the 
immunohistochemistry, so the approach was to screen for mutations in SDH genes (SDHB, SDHC, 
SDHD). Like in the Polish population, genotype-phenotype correlation was done to draw conclusions 
about the Portuguese population of PCC/PGL’s. 
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PART I 
 
PATIENTS AND CASES 
The cases included in the first part of the study comprised paraffin-embedded tissue from 61 PCC 
tumours belonging to 57 Polish patients. Personal and clinico-pathological information was provided 
by a pathologist including patient’s age and sex, as well as tumour location, size, histological features 
and microvessel density. 
Among the 57 patients diagnosed with PCC, 50 cases had no family history (88%) and the 
remaining 7 PCC’s were associated with familial syndromes (12%); in the latter, two patients 
presented with MEN2 (29%), four with NF1 (57%) and one with VHL syndrome (14%). 
Metastatic disease in PCC is defined by the presence of tumour cells in sites that normally do not 
contain chromaffin cells (Thompson 2002; Fishbein et al. 2012). Malignancy is usually identified using 
histologic observations of PCC, like increased necrosis, vascular and capsular invasion (defined by 
direct extension into the vessel lumen, intravascular attached tumour thrombi and/or tumour nests 
covered by endothelium in a capsular or extracapsular vessel), presence of mitotic figures (number of 
mitoses per 10 high power fields – HPF) and atypical mitotic figures, periadrenal adipose tissue 
infiltration, diffuse growth, high cellularity, presence of spindle cells, cellular monotony, cellular 
pleomorphism and nuclear hyperchromatosis (Jafri et al. 2012). Additionally, a Pheochromocytoma of 
the Adrenal Gland Scaled Score (PASS) is used for these specific histologic features and separates 
tumours with potential aggressive behaviour (PASS≥4) from biologically benign tumours (PASS<4), 
helping to predict prognosis. Thus, each feature accounts for a specific score if present in the tumour, 
as revealed in Table 1, which result in a final PASS score (1-20) for the PCC and allows the 
identification of benign or malignant one (Thompson 2002). 
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Table 1 – Pheochromocytoma of the Adrenal Gland Scoring Scale (PASS) (Thompson 2002). 
Histologic feature Score (if present) 
Diffuse growth 2 
Single cell necrosis 2 
High cellularity 2 
Cellular monotony 2 
Spindle cells 2 
More than 3 mitotic figures/10HPF 2 
Atypical mitotic figures 2 
Periadrenal adipose tissue infiltration 2 
Vascular invasion 1 
Capsular invasion 1 
Cellular pleomorphism 1 
Nuclear hyperchromatosis 1 
Total 20 
HPF – high power fields 
 
Microvessel density was also assessed in every tumour and scored using the Chalkley counting 
method. The Chalkley score was applied to count vessels under the capsule and in the middle of the 
tumour using mm2 as counting area.  
In this method tissue sections were stained for tumour vasculature and a Chalkley graticule was 
applied. Chalkley graticule is a circle with 25 dots randomly placed in a vascular area and the greatest 
number of vessels that coincide with this graticule is averaged for the three hotspot areas to define 
the Chalkley score (Jubb et al. 2006; Hayat 2010). 
This method uses antibodies against vascular endothelium for the assessment of tumour 
vascularity, detecting microvessel density (Hayat 2010). 
Tumour microvessel density may predict the risk of metastasis and serum levels of angiogenic 
factors may serve as tumour markers (Ranieri et al. 2001). Thus, different endothelial cell markers are 
used to evaluate microvessel density in tumours, such as anti-CD31 and anti-CD105 selected for this 
study (Hayat 2010) . 
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CD31 also known as PECAM-1 – platelet endothelial cell adhesion molecule-1 – is a membrane 
protein with 130 kDa and belongs to the immunoglobulin superfamily whose function is mediating 
cell-to-cell adhesion. This protein is expressed in the surface of adult and embryonic endothelial cells, 
bone marrow-derived hematopoietic stem cells, embryonic stem cells and weakly in peripheral 
leukocytes and platelets. CD31 is also involved in angiogenesis as mediator of endothelial cell-cell 
interactions (Vecchi 1994). 
CD105, known as endoglin is an endothelial membrane antigen expressed on the endothelial cells 
of capillaries, arterioles and venules as well as strongly expressed in blood vessels of tumour tissues. 
This glycoprotein is part of the transforming growth factor receptor complex whose function is to be 
receptor for TGFβ 1 and 3 and modulate TGFβ by interacting with TGFβ receptors I and II (Duff et al. 
2003). 
Specifically for the assessment of microvessel density, CD31 shows the vascular status of the 
tumour but they mark both neoformed vessels and normal preexistent vessels in normal and 
tumoural tissues, not indicating the angiogenic intensity; CD105 seems to be more specifically for the 
endothelial cells of neoformed vessels, as its expression increased with the angiogenic progression 
(Jung et al. 2009). 
 
METHODS 
IMMUNOHISTOCHEMISTRY 
Histopathology of the tumours was evaluated using 2μm sections and conventional Haematoxylin 
and Eosin (H&E) staining.  
The immunohistochemistry staining of SDHB and SDHA proteins in PCC tumour tissues was 
executed by Thermo Scientific/Lab Vision kit (Fremont, USA). 
Paraffin was dissolved by Clear Rite solution, followed by a series of ethanol’s (100%, 95% and 
70%) and running water that permeabilize and hydrate the tissues. Antigenic retrieval was performed 
using 1xEpitope Retrieval Solution pH 9 (Tris/EDTA-based buffer containing surfactant) (Leica 
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Microsystems, Newcastle Upon Tyne, United Kingdom) at 98°C for 20 min in water bath for SDHB and 
1 min at 98°C followed by 5 min at 125°C, in a pressure cooker for SDHA. Next, a series of blocking 
solutions were added: 3% hydrogen peroxide in methanol to block the endogenous peroxidase 
activity; Avidin-Block and Biotin-Block solutions (Thermo Scientific/Lab Vision, Fremont, USA) for 
endogenous biotin blockage and Large Volume Ultra V-Block (Thermo Scientific/Lab Vision, Fremont, 
USA) for non-specific binding blockage.  
Incubation with primary antibody was performed using mouse monoclonal antibodies specific for 
SDHA (Complex II subunit 70 kDaFp) and SDHB (Complex II subunit 30 kDaIp) from MitoSciences 
(Eugene, Oregon, USA). Negative (without primary antibody) and positive controls were used 
simultaneously to ensure specificity and reliability of the staining process. The antibodies were 
diluted in “Large Volume Ultra Ab Diluent” (Thermo Scientific/Lab Vision, Fremont, USA) using the 
exact dilution for each one and incubated for a specific time and temperature: SDHA – 1:1250, 1h at 
room temperature; SDHB – 1:600, overnight at 4°C (Table 2). 
Antigen detection was done with a labelled streptavidin-biotin immunoperoxidase detection 
system (Thermo Scientific/Lab Vision, Fremont, USA) using a secondary antibody “Biotinylated Goat 
Anti-Polivalent” and a streptavidin-peroxidase complex “Large volume Streptavidin Peroxidase”. 
Finally, an immunohistochemical staining with DAB chromogen (3,3’-diaminobenzidine) (Thermo 
Scientific/Lab Vision, Fremont, USA) was used followed by hematoxylin as counterstain to visualize 
the presence or absence of antibody-antigen binding. 
 
Table 2 – Immunohistochemistry for SDHB and SDHA. 
Protein Antigenic Retrieval 
Antibody 
Name Dilution Incubation 
SDHB 
Water Bath 
20 min 98°C 
Complex II subunit 30 kDa (MitoSciences) 1:600 ON 4°C 
SDHA 
Pressure cooker 
1min 98°C 
5min 125°C 
Complex II subunit 70 kDa (MitoSciences) 1:1250 1h RT 
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DNA EXTRACTION 
Slides with 10μm sections were immersed in Clear Rite to dissolve paraffin and then in 100% 
ethanol to wash the tissue. Next, tumour and normal tissue was microdisseced into different 
eppendorfs. Cell lysis solution (Citomed, Lisbon, Portugal) and 180μg/ml proteinase K (Fermentas, 
Thermo Fisher Scientific) was added to each sample in order to digest the cells at 55°C overnight. 
After lysis and digestion, a protein precipitation solution (Citomed, Lisbon, Portugal) was added to 
each eppendorf and, after centrifugation (16000g, 3min., 4°C), supernatant was transferred to 
another eppendorf. In the new eppendorfs, DNA was precipitated after adding isopropanol (1x 
volume) and 10μg/ml glycogen (Fermentas, Thermo Fisher Scientific). After centrifugation (3x 16000g, 
10min., 4°C), the DNA pellet was washed with 70% ethanol and finally eluted in deionized water and 
quantified in NanoDrop Spectrophotometer ND-1000 (Thermo Scientific, Fremont, USA). 
 
PCR – POLYMERASE CHAIN REACTION 
Polymerase Chain Reaction was used to amplify the exon and exon boundaries of the genes of 
interest. The Qiagen® Multiplex PCR kit was used, according to manufacturer’s instructions. 
Amplifications were performed using 2x Qiagen Multiplex Master Mix (10µL), 5x Q-Solution (2µL), 1x 
forward and reverse primers (1µL) and template DNA (10-100 ng/µL) in a 20 µL reaction volume.  
Cases with familial history of MEN2 and VHL syndrome, were screened for mutations in RET and 
VHL genes, respectively. Cases showing a negative immunostaining for SDHB protein were screened 
for mutations in SDH genes (except SDHA gene), beginning with a recently found large deletion in 
SDHB gene comprising promoter and exon 1 with Portuguese origin. All samples presenting this 
deletion were then tested for the haplotypic variability in the flanking regions upstream and 
downstream of the deletion breakpoint, already identified among the previous cases showing this 
mutation, in order to demonstrate the same haplotype of all cases. When the deletion was not 
present, SDHB gene was tested for other mutations, followed by SDHD and finally SDHC genes as the 
most suitable procedure. Finally, cases without SDH, MEN2, NF1 and VHL syndrome associated were 
screened for mutations in TMEM127 and MAX genes. 
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Primers used for SDHB large deletion, haplotype analysis and RET (exons 11 and 16), VHL, SDHB, 
SDHC, SDHD, SDHAF2, MAX and TMEM127 genes are listed in Table 3.  
Six independent multiplex reactions were performed for simultaneous amplification of exons 1-4 
of SDHD, exons 1-4 and 5-8 of SDHB, exons 1-3 and 4-6 of SDHC and exons 1-4 of SDHAF2. 
For MAX and TMEM127, exons were amplified individually using the same Multiplex PCR kit (exon 
1 of TMEM127 was not amplified since it is a non-coding exon). 
The mixture was heated for 15 minutes at 95°C for initial DNA denaturation, followed by 35 or 40 
cycles (depending on the tissue quality ) of denaturation (30 sec at 95°C), annealing (90 sec at the 
following temperatures: RET exon 16 at 55°C; SDHB at 60°C; SDHC and SDHAF2 at 58°C; SDHD at 56°C; 
MAX exons 1 and 3 at 65°C, exons 2 and 4 at 61,1°C and exon 5 at 58,7°C; TMEM127 exons 2 and 4 at 
63°C and exon 3 at 58,7°C) and extension (90 sec at 72°C); the last step is the final extension at 72°C 
for 10 min. Annealing for RET exon 11 and VHL was done by touchdown in cycles of 90 sec, beginning 
with 64°C for 2 cycles, 62°C for 3 cycles and 60°C for 35 cycles in the RET gene; 62°C for 2 cycles, 60°C 
for 3 cycles and 58°C for 35 cycles in the VHL gene. 
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Table 3 – Primers sequences for SDHB large deletion (promoter and exon 1) and haplotype; VHL, RET (exon 11 and 16), 
SDHB, SDHC, SDHD, SDHAF2, MAX and TMEM127 genes. 
Primer name Primer sequence 
SDHB 
Deletion promoter+exon 1 
5UPUP StreamF AGCGCCAATTGTGGAAATAG 
BREAK R GCCTGAGGCAGATAGTAGGG 
Haplotype 
5UPUP StreamF AGCGCCAATTGTGGAAATAG 
Intron 1.2R CCCTACCTCCCCTGTACTCC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primer name Primer sequence 
VHL 
1F TGGTCTGGATCGCGGAGG 
1R CTAAGCGCCGGGCCCGT 
2F ACAACCTTTGCTTGTCCCGA 
2R AGTGGTCTATCCTGTACTTACCA 
3F ACCCTAGTCTGCCACTGAGGA 
3R AGCTGAGATGAAACAGTGTAAGT 
RET 
hotspots 
11F CCCAGTGGTGCCGAGCCTCT 
11R GTGGATGCAGAAGGCAGACAGC 
16F CCTCCTTCCTAGAGAGTTAGAGT 
16R AAGAGAGCAACACCCACACT 
SDHB 
1F GGTCCTCAGTGGATGTAGGC 
1R ACTTTTCCCTCTCTGAGGCT 
2F GCGTTACATCTGTTGTGCCA 
2R AGCTGGCTTTCACAGAGATAC 
3F ACATCCAGGTGTCTCCGATT 
3R AGCCCAACAGGAATGAAATG 
4F TGATTCCGGATATGGGTGAG 
4R ACCAGAGAGATGCAGAAACTC 
5F GCTGAGGTGATGATGGAATCT 
5R AGCCACACTCCTGGCAATCA 
6F ATAGCAGAGTCTCTCCCGTC 
6R AGCAATTAAGGAGCACCTCA 
7F CTCAGCTAATCATCCCTGGT 
7R TCTGGCGTGTCAGCTCTGA 
8F AGGAAGGAGTTTCACCCAAG 
8R ATGTTCAGCTCTGAGCTGGT 
SDHC 
1F ACTTCCGTCCAGACCGGAA 
1R AACGTGAGGGGCCAGTTCA 
2F AGTTGATCTCTAAATGTGTATTGA 
2R AATAATCTCCAGACTTAGAAACTT 
3F ATGCCTGGCTTGGTATTGCAA 
3R ATTCTCTGGCTCCAGAATCCT 
4F TAGACTCTCTACTATGGTGTCA 
4R TAGGGCCAATGAAACAGCCAA 
5F AGCTGTGACAAGCTACTTGGT 
5R AATGTGCAAATCCCGAATTAACT 
6F AGACAGGAACTGTTAATGTCCT 
6R TGTAGGAAGATGATGCTGGGA 
Primer name Primer sequence 
SDHD 
1F TGACCTTGAGCCCTCAGGAA 
1R TCAGGGTGGGAAGACCCCT 
2F GATCATCCTAATGACTCTTTCC 
2R AGCAGCAGCGATGGAGAGAA 
3F CTTTTATGAATCTGGTCCTTTTTG 
3R CAACTATATTTGGAATTGCTATAC 
4F TGATGTTATGATTTTTTCTTTTTCT 
4R CAATTCTTCAAAGTATGCAGTCA 
SDHAF2 
1F AGTCCGGACTAGGCCCGAA 
1R ACGCTAGAACGTTCTCTCTCCT 
2F TGATAGCGATGATAGTCGTCATT 
2R GAGTCTCTCTGAACCTACTCT 
3F AGAGTAGGTTCAGAGAGACTC 
3R TCAAATCAGCCTAAACTGTCCTA 
4F AGCATTGACTGACTATGGCATAA 
4R TAGTTACCATCCACAGACTGAA 
MAX 
1F GGGACTCGGGCTTGTTGTTGTCGG 
1R CGTCGCCCCGCTAAGAGCC 
2F CGCTCGGGACCCCTCTACCC 
2R GGCCCCACCTCACCTTAGTGGT 
3F CCAGGCTGTACCCCACCCACC 
3R AGTGCTCTGCTAAGCTCTGCAACAA 
4F AGGCCAGGTTCCCTCACTGCC 
4R CCCAGGTGCCAAAGCCTGACC 
5F TCCCCAAGTCTCCAGAAGGCAGT 
5R AGGAGGATGAGACGATGGAGACAGA 
TMEM127 
1F AGGCAGAGGAGGAGGAAGC 
1R GACCTGTGCGCAGAAAAGAC 
2F CCCCTATCCTCTGGTGTCAA 
2R CTGGTCCCTGGCTATCTCTG 
3F GCCGTGAAAATTTGGTTCTC 
3R CCACCCTGTAGCAGTTCCTC 
4F GTGCTGTCCCTCTGTCTCCT 
4R GAGGAGCTGCAGAGTTGAGG 
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AGAROSE GEL ELECTROPHORESIS 
2% agarose gels were made using 1x SGTB (Grisp, Oporto, Portugal) to dissolve the agarose (Lonza) 
after heating, and adding GelRed (Biotium, Hayward, California) to the gel, a fluorescent nucleic acid 
gel stain. Sample preparation requires a mixture of 6x loading buffer (stock solution: 40mL glycerol 
87%, 60mL H2O and 0,25g bromophenol blue) and DNA in a 1:2 dilution. After loading the samples in 
the gel, a voltage of 120V was applied to run the samples for 25 min and the gel was analysed with 
UV light using the ChemiDocTM XRS System (Bio-Rad) to confirm successful amplifications. 
 
SEQUENCING 
PCR products underwent a purification treatment using 1U/µL exonuclease I (Fermentas, Thermo 
Fisher Scientific) and 1U/µL shrimp alkaline phosphatase (Fermentas, Thermo Fisher Scientific) at 
37°C for 20 minutes, followed by heat inactivation for 15 minutes at 80°C. 
Automatic sequencing was performed using the BigDye terminator v3.1 cycle sequencing kit 
(Applied Biosystems, Carlsbad, California), Sequencing buffer (Applied Biosystems, Carlsbad, 
California) and the same primers used in PCR assay, in a sequence of steps: initial denaturation for 30 
sec at 95°C; 35 cycles of denaturation (10 sec at 95°C), annealing (10 sec at 55°C) and extension (2 
min at 60°C); and a final extension at 60°C for 10 min. The sequencing products were finally purified 
with Sephadex G-50 Fine (GE Healthcare), resuspended in formamide (Applied Biosystems, Carlsbad, 
California), and ran in automated sequencer ABI PRISM 3130 Genetic Analyser (Applied Biosystems, 
Carlsbad, California). 
 
MLPA - MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION 
MLPA was used to search for large deletions in SDH genes using P226-025R MLPA probemix lot B2 
1111 (MRC-Holland, Amsterdam, Netherlands). 
MATERIALS AND METHODS 
51 
 
All DNA’s used in this technique had a concentration of 10 to 50ng/µL and underwent a 
denaturation step at 98°C for 5min. A blank sample (without DNA) was used to ensure that all 
solutions from MLPA kit were not contaminated. Then, in the hybridization step, 1,5µL MLPA buffer 
(MRC-Holland, Amsterdam, Netherlands) and 1,5µL MLPA probemix (MRC-Holland, Amsterdam, 
Netherlands) was added to the DNA’s at 25°C. This hybridization occurred when the samples were 
heated at 95°C for 60sec followed by 16-20h at 60°C. The subsequent stage was ligation which 
consists of adding a mix composed by 3µL ligase buffer A (MRC-Holland, Amsterdam, Netherlands), 
3µL ligase buffer B (MRC-Holland, Amsterdam, Netherlands), 1µL ligase 65 (MRC-Holland, 
Amsterdam, Netherlands) and dH2O at 54°C for 15min and then heated to 98°C for 5min. The final 
step was a PCR following “one-tube protocol” given by the manufacturer’s instructions that consists 
of preparing a mix with 4µL Salsa PCR buffer (MRC-Holland, Amsterdam, Netherlands) and dH2O, 
added to the samples at 60°C. 2µL Salsa PCR primer (MRC-Holland, Amsterdam, Netherlands), 2µL 
Salsa enzyme Dilution Buffer (MRC-Holland, Amsterdam, Netherlands), 0,5µL Polymerase (MRC-
Holland, Amsterdam, Netherlands) and dH2O were mixed and added to each one of the PCR tubes 
that consequently underwent 35 cycles of denaturation (30 sec at 95°C), annealing (30sec at 60°C) 
and extension (60sec at 72°C) and a final extension step at 72°C for 20min.  
Finally, 0,5µL size standard 500LYZ 3130 (Applied Biosystems, Carlsbad, California), dH2O and 
formamide (Applied Biosystems, Carlsbad, California) were added to MLPA/PCR products and the 
fragments were analysed using ABI-Prism 310 Genetic Analyser (Applied Biosystems, Carlsbad, 
California). 
MLPA results were analysed by Gene Mapper Applied Biosystems, Carlsbad, California), Peak 
Scanner Applied Biosystems, Carlsbad, California) and Coffalyser Softwares (MRC-Holland, 
Amsterdam, Netherlands). 
Coffalyser software performed the ratios calculation for each probe, specific for chromosome 
positions comprising SDHB, SDHC, SDHD and SDHAF2 exons. After performing MLPA for three times 
under the same conditions, mean ratios were calculated for all probes of each sample (Table 6 in the 
Results part). Results interpretation was based on information available by MRC-Holland which 
associates generated ratios with copy number status (Table 4). 
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Table 4 – Interpretation of ratios calculated by MLPA assay. 
Copy Number Status Ratios 
Normal 0,85 – 1,15 
Heterozygous Deletion 0,35 - 0,65 
Homozygous Deletion 0 – 0,35 
Heterozygous Duplication 1,35 – 1,55 
Homozygous Duplication 1,70 – 2,20 
Equivocal Copy Number All other values 
 
 
STATISTICAL ANALYSIS 
Statistical significance was examined by Pearson chi-square test and T-test for genotype-
phenotype correlations. In all analysis p<0,05 was considered statistically significant. 
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PART II 
PATIENTS AND CASES 
The second part of this study includes 12 blood samples from Portuguese PGL patients and 
respective clinical information, including sex, age, tumour type and local, as well as malignancy. 
 
METHODS 
DNA ISOLATION 
Genomic DNA was extracted from peripheral blood, using a salt-precipitation method. First, 
erythrocytes were lysed by adding 45ml of 1xAKE (stock solution: 155mM of NH4Cl, 10mM of KHCO3 
and 1mM pH 7,4 of EDTA) to 5ml of blood sample for 1h at 4°C. Samples were then centrifuged 
(2500rpm, 20min.) to remove the erythrocytes membranes and form a pellet of white blood cells. 
Next, 1% SDS (v/v) and 180μg/ml proteinase K (Fermentas, Thermo Fisher Scientific) were added to 
the pellet, in order to lyse the membranes and digest proteins, respectively; this step was performed 
at 55°C, overnight with shaking. Finally, proteins were precipitated after adding a pre-heated 
saturated solution of 1.2M NaCl, an equal volume of chloroform and shaking for 30 minutes at room 
temperature. After centrifugation (2500rpm, 10min.), supernatant was removed to another tube and 
the DNA was precipitated by adding isopropanol (1x volume); DNA pellet was then washed in 70% 
ethanol, eluted in deionized water and quantified in NanoDrop Spectrophotometer ND-1000 
(ThermoScientific, Fremont, USA). 
 
PCR / AGAROSE GEL ELECTROPHORESIS / SEQUENCING / STATISTICAL ANALYSIS 
DNA amplification, gel electrophoresis and sequencing techniques, as well as statistical analysis 
were performed according to the same methodology explained in the previous part. 
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PART I 
PATIENT AND TUMOUR CHARACTERISTICS  
Clinical features 
The mean age at diagnosis was 48 years with a range from 19 to 75 years. There was a similar 
prevalence of male and female patients with PCC (49% of females and 51% of males). The majority of 
patients had unilateral tumours (93%), followed by bilateral tumours (5%) and only one case of 
multiple PCC (2%); the mean tumour size was 5,03cm. From the 61 tumours, the majority were 
located in the right adrenal gland (56%) and the others were located in the left side (38%); in four 
tumours (6%) no information about the location was available. Additionally, tumours developed in 
the right adrenal gland (mean=4,4cm) were significantly minor than those within the left adrenal 
gland (mean=6,1cm) (p=0,006). Metastases were found in only three patients with PCC (5%): one had 
liver metastasis, another had liver, lung and bone metastasis and the third patient had metastasis at 
the opposite side of the adrenal tumour. Relapse occurred in three patients (5%). 
 
Tumour histologic features 
Using the PASS scoring method, a mean score of 4 was found taking into account all the tumours. 
This score labels tumours as potential aggressive (≥4) or benign (<4); in this study the frequency of 
cases presented as potential aggressive tumours was 56% and benign tumours was 44%. 
The results showed that nuclear hyperchromatosis (71%), spindle cells (64%) and cellular 
pleomorphism (53%) were the features more frequently present in this series of PCC’s. Other 
histologic observations were also found: 30% of the cases exhibited diffuse growth, 23% showed 
capsular invasion, cellular monotony was present in 20% of the tumours, high cellularity was present 
in 13% of the tissues, 10% of the cases had periadrenal adipose tissue infiltration, vascular invasion 
was present in 8%, cellular necrosis and mitotic figures (>3/10HPF) were in 3% of the cases and finally 
atypical mitotic figures were not seen in any tumour. More than 3 mitotic figures/10HPF were 
present only in two tumours with 7-8 and 4 mitotic figures, each; cellular necrosis was found in only 
two cases. 
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Tumour microvessel density 
Under the capsule, CD31 showed a mean vessel density of 40,34 vessels/mm2, while CD105 
showed a mean vessel density of 23,56 vessels/mm2; in the middle of the tumour CD31 marked a 
mean vessel density of 46,09 and CD105 presented a mean vessel density of 33,09. 
 
IMMUNOHISTOCHEMISTRY  
Immunohistochemistry of 61 paraffin-embedded tissues from 57 PCC patients was performed for 
SDHB and scored in positive (1 plus, 2 plus or 3 plus) or negative according to the amount of antibody-
antigen binding for SDHB protein in tumour cells (Table 5). This procedure was performed in order to 
identify the cases with germline SDH mutations, since the presence of such mutations are closely 
associated with loss of SDHB expression. The staining revealed 3 negative tumours (5%) (Figure 4) and 
58 positive cases (95%). Positive cases showed cytoplasmic and granular staining of SDHB, consistent 
with a mitochondrial pattern. Among the 58 positive cases, 10 were scored as 1 plus (17%) (Figure 
6A), 13 with 2 plus (23%) (Figure 6B) and the majority of the cases with a 3 plus score (57%) (Figure 
6C). Only 2 cases were classified as 2 and 3 plus simultaneously, since it was difficult to differentiate 
them in one of the classes (3%). The three cases without SDHB expression did not show evidence of 
MEN2, NF1 or VHL. 
 
Table 5 – Immunohistochemistry results for SDHB expression in 61 tumour tissues from 57 PCC patients. 
SDHB expression 
All tumours 
(n=61) 
Negative 3 (5%) 
Positive 58 (95%) 
1+ 10 (17%) 
2+ 13 (23%) 
2+/3+ 2 (3%) 
3+ 33 (57%) 
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Immunohistochemistry for SDHA protein was performed in the three SDHB negative cases, in 
order to discard SDHA as the mutated gene causing PCC. Whenever there is a mutation in SDHB, 
SDHC or SDHD, there is loss of SDHB expression, while SDHA is still expressed; on the other hand, in 
the presence of a SDHA mutation there is loss of both SDHB and SDHA. The immunohistochemistry 
showed positive expression of SDHA protein in the three SDHB-negative cases, discarding any SDHA 
mutations (Figure 5). 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 5 – Positive immunohistochemistry for SDHA protein in the three PCC cases without SDHB expression. 
 
A B C 
Figure 6 – Positive immunohistochemistry for SDHB protein in three PCC cases. A 
– 1 plus score; B – 2 plus score; C – 3 plus score 
A B C 
Figure 4  - Negative immunohistochemistry for SDHB protein in three PCC cases. 
A B C 
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MOLECULAR GENETICS OF PCC CASES 
Cases with positive familial history 
Regarding the molecular genetics approach, the first criterion used to select the most probable 
gene was the presence of familial/personal history compatible with NF1, MEN2 or VHL. 
Four NF1 patients (one of them with a bilateral PCC) were diagnosed solely based on clinical 
criteria, since NF1 gene is very large and without hot spots, making it extremely difficult to perform 
genetic screening of the disease. Two cases (both with bilateral PCC’s) were clinically diagnosed with 
MEN2 syndrome and both were found to carry a germline RET mutation: one patient carried a 
missense mutation in exon 16 - c.2753T>C, p.M918T - indicating a MEN2B situation (Figure 7), while 
the other patient harboured a missense mutation in exon 11 – c.1901G>A, p.C634Y - that is indicative 
of MEN2A syndrome (Figure 8). The patient with VHL syndrome was screened for mutations in VHL 
gene, but PCR amplification of tumour DNA was not possible, perhaps due to poor quality of material. 
 
 
Figure 7 – RET mutation in exon 16 (c.2753T>C, p.M918T). 
 
 
 
Figure 8 - RET mutation in exon 11 (c.1901G>A, p.C634Y). 
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Cases without familial history (apparently sporadic) 
In the cases that did not show evidence of NF1, MEN2 or VHL, the absence of SDHB expression 
was used to select the cases to be screened for SDH mutations. The three PCC cases that showed loss 
of protein expression were tested for mutations in SDH genes, in order to find the underlying 
pathogenic mutation variant. 
The first genetic alteration to be assessed was a large deletion in the SDHB gene, comprising the 
promoter region and exon 1, removing 15678bp; this alteration was recently identified in a large 
proportion of Portuguese PGL/PCC patients and previously described by Cascón et al. All three PCC 
cases were negative for this deletion. Next, the entire coding regions and exon-intron boundaries of 
SDHB, SDHD, SDHC and SDHAF2 genes were sequenced, but no variants were detected. The next step 
was to look for the presence of large deletions using MLPA assay, which includes a probemix for all 
SDH genes.  
Two out of three samples were identified as carrying large deletions: one of them had an exon 4B 
deletion in SDHC and an exon 4 deletion in SDHD; the second one had an exon 4B deletion in SDHC 
(Table 6). In the remaining sample, despite the absence of SDHB expression, no SDH mutations were 
disclosed (Table 6).  
SDHC exon 4B deletion comprised 400 nucleotides deletion and was detected in two samples, one 
of them also carrying the large deletion mentioned above. This SALSA MLPA probe in the 
chromosome position 01q23.3, includes 2 ligation sites to cover a large area (>10kb) that comprise 
introns surrounding the exon 4. Also, the probe has a quite low Tm and thus, can be variable, as 
target sequence can carry a SNP which easily affects the binding of the probe, resulting in a reduced 
probe signal. To obtain specific conclusions for this deletion, it was recommended to check the target 
sequence for SNP’s, which was not possible to perform. Thus, this deletion was not considered as a 
true pathogenic variant for this study. 
Although only one sample was considered as carrying an SDH mutation, the three cases with 
negative SDHB immunohistochemistry were considered for genotype-phenotype correlations, as they 
had absent SDH expression. 
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Table 6 – MLPA results for SDH large deletions. 
Exon 
Chromosome 
position 
Length (nt) 
Ratios 
Sample 1 Sample 2 Sample 3 
SDHB Exon 1A 01p36.13 344 1,79 1,69 2,31 
SDHB Exon 1B 01p36.13 166 1,61 1,19 1,85 
SDHB Exon 2 01p36.13 226 1,37 1,18 1,15 
SDHB Exon 3 01p36.13 208 1,06 0,93 0,79 
SDHB Exon 4 01p36.13 263/373 1,23 0,87 0,91 
SDHB Exon 5 01p36.13 256 1,00 1,21 0,79 
SDHB Exon 6 01p36.13 238 0,98 1,08 0,88 
SDHB Exon 7 01p36.13 328/337 1,15 1,19 1,04 
SDHB Exon 8 01p36.13 190 1,17 1,05 0,84 
SDHC Promotor 01q23.3 138/142 1,11 1,18 2,30 
SDHC Exon 1 01q23.3 355 1,28 1,02 2,07 
SDHC Exon 2 01q23.3 182/184 0,80 0,79 0,73 
SDHC Exon 3A 01q23.3 382 0,94 0,71 0,81 
SDHC Exon 3B 01q23.3 270 0,90 0,70 0,80 
SDHC Exon 4A 01q23.3 148 1,05 0,85 0,85 
SDHC Exon 4B 01q23.3 400 1,19 0,25 0,30 
SDHC Exon 5 01q23.3 292 0,93 0,81 0,92 
SDHC Exon 6 01q23.3 247 0,81 1,01 1,23 
SDHD Promotor 11q23.1 318/326 0,90 0,68 1,69 
SDHD Exon 1 11q23.1 160/178 1,00 0,73 1,98 
SDHD Exon 2 11q23.1 172 0,97 0,84 1,41 
SDHD Exon 3 11q23.1 311/319 0,81 0,66 1,00 
SDHD Exon 4 11q23.1 214 0,84 0,06 0,84 
SDHAF2 Exon 1 11q12.2 160 0,91 0,90 2,03 
SDHAF2 Exon 3 11q12.2 391 0,83 0,71 1,19 
SDHAF2 Exon 4 11q12.2 418 0,87 0,70 1,55 
SDHAF1 19q13.12 136 1,2 1,07 1,13 
 
Finally, the 48 remaining cases (61 tumour tissues excluding the three SDH, five NF1, four MEN2 
and one VHL) were submitted to Sanger sequencing for MAX and TMEM127 genes, as they constitute 
two novel susceptibility genes related with PCC/PGL’s. 
For the MAX gene, 26 tumour DNAs were sequenced for all 5 exons; for technical reasons, in 15 
tumours only part of the gene was sequenced, while in seven cases MAX sequencing could not be 
performed. For the TMEM127 gene, all exons, except for exon 1 (non-coding exon), were sequenced 
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in 14 tumour DNAs; for technical reasons, in 28 cases TMEM127 was incompletely sequenced and in 
six cases were impossible to perform sequencing. 
No pathogenic mutation was detected in any of the two genes. A synonymous variant in exon 4 of 
TMEM127 gene (c.621G>A; p.A207A) was detected in 7 cases (12%) (Figure 9); this alteration is a 
previously reported SNP, with an allele frequency of 18% in European populations (Neumann et al. 
2011). 
 
 
Figure 9 – SNP in TMEM127 exon 4 (c.621G>A; p.A207A). 
 
Genotype-phenotype correlation 
After genetic analysis, genotype was associated with phenotype by comparing mutated with non-
mutated cases (Table 7, 8 and 9). Mutated cases comprised 10 patients (18%) with familial history: 
three of them with loss of SDH expression, four NF1 patients, two MEN2 with missense mutations in 
RET gene and one VHL with possible loss of gene expression. The remaining 47 (82%) cases comprised 
non-mutated cases and thus termed sporadic cases. 
As depicted in Table 7, the mean age at diagnosis was not significantly different between mutated 
and non-mutated cases, although mutated cases had a lower mean age at diagnosis than non-
mutated cases (41 vs. 50, respectively, p=0,090). Among the mutated cases, SDH patients had a mean 
age at diagnosis of 38 years, MEN2 patients presented a mean age of 29, NF1 patients showed a 
mean age of 54 and the VHL case developed in a 19 years old individual. Excluding NF1 patients that 
had an age at diagnosis comparable to that of sporadic cases, mutated cases had a significantly 
younger age at diagnosis than cases without familial history (p=0,006). 
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Among the non-mutated cases there was a similar prevalence of male and female patients with 
PCC (51% of females and 49% of males); among the mutated cases there was higher frequency of 
males than females (40% of females and 60% of males), but without statistical significance (p=0,730). 
MEN2 patients had an equal frequency of males and females (50%), NF1 cases comprised more males 
(75%) than females (25%) and VHL and SDH mutated cases affected only male patients. 
There was a significantly higher frequency of bilateral tumours in mutated cases, when compared 
to non-mutated cases (30% vs. 0%, p=0,015). The only multiple tumour was found in a non-mutated 
case. SDH patients had only unilateral tumours, MEN2 cases presented only bilateral PCC’s, NF1 
patients had 3 unilateral (75%) and 1 bilateral tumour (25%) and the VHL patient had an unilateral 
PCC. 
The mean tumour size of mutated cases was 4,42cm and non-mutated cases had a mean tumour 
size of 5,20cm, without statistically significant differences (p=0,295). The larger tumours belonged to 
NF1 patients with a mean size of 5,26cm, followed by MEN2 tumours with a mean size of 4,88cm, 
SDH tumours with 3,27cm and finally the only VHL tumour with a size of 1,8cm. 
Mutated and non-mutated cases followed the same tendency, with a predominance of tumours in 
the right side and thus without significant differences for tumour location (p=0,657). MEN2 cases had 
equal frequencies for the two adrenal glands since the patients had bilateral tumours, NF1 patients 
had more frequency of tumours in the right (60%) than in the left adrenal gland (40%) and SDH and 
VHL cases had tumours located only in the right adrenal gland. 
Metastasis were found in only three patients with PCC (6%) all with sporadic disease; relapse 
occurred in three patients, one of them a NF1 case (10%) and the other two sporadic cases (4%).  
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Table 7 – Correlation of clinical features between mutated and non-mutated patients. 
Clinical 
features 
Non-mutated 
patients 
(n=47) 
Mutated cases P-value 
All 
patients 
(n=10) 
MEN2 
patients 
(n=2) 
NF1 
patients 
(n=4) 
VHL 
patient 
(n=1) 
SDH 
patients 
(n=3) 
Mutated patients 
Vs Non-mutated 
patients 
Gender 
F 
M 
 
24 (51%) 
23 (49%) 
 
4 (40%) 
6 (60%) 
 
1 (50%) 
1 (50%) 
 
3 (75%) 
1 (25%) 
 
0 
1 (100%) 
 
0 
3 (100%) 
p=0,730 
Age 
Range 
Mean 
 
19-75 
50 
 
20-70 
41 
 
20-37 
29 
 
45-70 
54 
 
- 
19 
 
28-50 
38 
p=0,090 
Tumour Type 
Unilateral 
Bilateral 
Multiple 
Total number 
of tumours 
 
46 (98%) 
0 
1 (2%) 
 
48 
 
7 (70%) 
3 (30%) 
0 
 
13 
 
0 
2 (100%) 
0 
 
4 
 
3 (75%) 
1 (25%) 
0 
 
5 
 
1 (100%) 
0 
0 
 
1 
 
3 (100%) 
0 
0 
 
3 
p=0,015 
Tumour Size 
Range 
Mean 
 
1,5-13,0 
5,20 
 
1,5-10,0 
4,42 
 
1,5-8,0 
4,88 
 
2,8-10,0 
5,26 
 
- 
1,8 
 
2,8-3,5 
3,27 
p=0,295 
Tumour 
Location 
Left 
Right 
No info 
 
19 (40%) 
25 (52%) 
4 (8%) 
 
4 (31%) 
9 (69%) 
0 
 
2 (50%) 
2 (50%) 
0 
 
2 (40%) 
3 (60%) 
0 
 
0 
1 (100%) 
0 
 
0 
3 (100%) 
0 
p=0,657 
Metastasis 3 (6%) 0 0 0 0 0  
Relapse 2 (4%) 1 (10%) 0 1 (25%) 0 0  
 
 
Table 8 shows that both mutated and non-mutated cases had a mean PASS score of 4. Tumours 
from mutated cases did not show high cellularity, vascular invasion and periadrenal adipose tissue 
infiltration. However, diffuse growth, cellular monotony, presence of spindle cells and pleomorphism 
were more frequent comparing with non-mutated tumours. More than 3 mitotic figures/10HPF were 
present only in two tumours, one sporadic and one familial (MEN2) with 7-8 and 4 mitotic figures, 
respectively; cellular necrosis was found in only two cases belonging to a non-mutated tumour and 
the same MEN2 case previously referred. The other features had higher frequencies in mutated 
tumours, namely capsular invasion and hyperchromatosis. However, no significant differences were 
seen in any histologic feature comparing mutated with non-mutated cases. 
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Table 8 - Correlation of tumour histologic features between mutated and non-mutated tumours. 
Tumour histologic 
features 
Mutated 
tumours 
(n=13)
a 
Non-mutated 
tumours 
(n=48)
b 
P-value 
Mutated tumours Vs 
Non-mutated tumours 
Diffuse growth 4 (31%) 14 (30%) n.s.s. 
Single cell necrosis 1 (8%) 1 (2%) p=0,384 
High cellularity 0 8 (17%) p=0,184 
Cellular monotony 3 (23%) 9 (19%) p=0,707 
Tumour spindle cells 11 (85%) 28 (58%) p=0,109 
More than 3 mitotic 
figures/10HPF 
1 (8%) 1 (2%) p=0,384 
Atypical mitotic figures 0 0 - 
Periadrenal adipose 
tissue infiltration 
0 5 (10%) p=0,575 
Vascular Invasion 0 5 (10%) p=0,575 
Capsular Invasion 2 (15%) 12 (25%) p=0,713 
Cellular pleomorphism 8 (62%) 24 (50%) p=0,541 
Nuclear 
hyperchromatosis 
8 (62%) 35 (73%) p=0,499 
Mean PASS score 
(0-20) 
4 4 p=0,826 
PASS (<4) 
Mean 
6 (46%) 
3 
21 (44%) 
2 
 
PASS (≥4) 
Mean 
7 (54%) 
6 
27 (56%) 
6 
 
   n.s.s. – not statistically significant 
a
13 tumours from 10 familial patients 
b
48 tumours from 47 sporadic patients 
 
Finally, microvessel density was also used to compare mutated with non-mutated tumours (Table 
9). Considering CD31 staining, it was shown that non-mutated cases presented significantly higher 
vessel density than mutated cases, under the capsule (p=0,028). The same was not observed for the 
CD105 marker (Table 9). 
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Table 9 - Correlation of microvessel density between mutated and non-mutated tumours. 
Number of vessels 
Mutated 
tumours 
(n=13)
a 
Non-mutated 
tumours 
(n=48)
b 
P-value 
Mutated 
tumours Vs Non-
mutated tumours 
Chalkley score/mm
2
    
Under the capsule 
CD31 Mean 
CD105 Mean 
 
33,03 
20,93 
 
42,32 
24,27 
 
p=0,028 
p=0,410 
Middle of the tumour 
CD31 Mean 
CD105 Mean 
 
39,90 
32,12 
 
47,76 
33,36 
 
p=0,083 
p=0,798 
   
a
13 tumours from 10 familial patients 
b
48 tumours from 47 sporadic patients 
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PART II 
PATIENT AND TUMOUR CHARACTERISTICS  
For the second part of this Thesis, 12 blood samples from Portuguese PGL/PCC patients were 
screened for SDH genes.  
Clinical information including sex, age, tumour type and localization is summarized in Table 10. 
This series was constituted of PGL’s and PCC’s. Three PGL’s were located in the head and neck 
region (50%), one in the pancreas (17%) and one in the retroperitoneum (17%), while one case did 
not have information regarding location; the remaining six cases were PCC’s. There was an equal 
female to male ration and the mean age at diagnosis was 41 years with a range between 15 and 63. 
There were two malignant tumours (17%), both PCC cases, one male patient with 15 years old and a 
female patient with 44 years old. 
Two cases had familial history, one bilateral PCC belonging to a male patient with 28 years old 
whose index case was his father presenting also a bilateral PCC; the other familial case was a PGL 
from a male patient with 15 years old whose index case was his mother. 
 
Table 10 – Clinical features from 12 PGL/PCC patients. 
Clinical features 
All patients 
(n=12) 
Gender 
F 
M 
 
6 (50%) 
6 (50%) 
Age 
Range 
Mean 
 
15-63 
41 
Tumour Type 
PGL 
Head and Neck 
Pancreas 
Retroperitoneal 
Extra-adrenal 
PCC 
Bilateral 
 
6 (50%) 
3 (50%) 
1 (17%) 
1 (17%) 
1 (17%) 
6 (50%) 
1 (17%) 
Malignancy 2 (17%) 
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MOLECULAR GENETICS 
In accordance with Part I of the Results, the first molecular alteration to be assessed was the SDHB 
large deletion comprising promoter region and exon 1, as it is a frequent variant in northern 
Portuguese PGL/PCC tumours. Afterwards, in cases that did not present this large deletion, SDHB, 
SDHD and SDHC genes were tested for mutations, in this order. 
The results showed that two cases (17%) carried the SDHB large deletion (c.1-10413_73-3866del), 
one being a bilateral head and neck PGL from a 53 year old female patient (MASC) and the other one 
a patient with malignant PCC with 15 years (MAMR). As the deletion encompasses a large region of 
SDHB gene, primers were designed selectively to amplify the deleted allele, only when the deletion is 
present. Thus, when amplification occurred, deletion was present and when deletion was absent, 
primers were unable to amplify the large region (Figure 10). Sequencing the region amplified by this 
pair of primers showed the breakpoint of the deletion (Figures 11 and 12). 
 
 
 
Figure 10 – Gel electrophoresis for SDHB exon 1 and promoter deletion (sample, control, blank and ladder). 
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Figure 11 – Scheme of SDHB large deletion (c.1-10413_73-3866del). 
 
 
 
 
Figure 12 – Breakpoint in SDHB exon 1 + promoter large deletion of MASC and MAMR patients. 
 
 
Additionally , one (8%) patient with head and neck PGL (APFC) was found to harbour a missense 
mutation in exon 1 of SDHB gene (c.32G>A; p. R11H) (Figure 13); another patient (8%) with a 
retroperitoneal PGL (PMOV), presented a frameshift mutation in exon 6 of SDHB gene (c.591 del.C; 
p.S198AfsX22) (Figure 14); finally, a patient (8%) with 15 years who developed PGL and had familial 
history (AEMS), showed a missense mutation in exon 1 of SDHD gene (c.3 G>C; p.M1I) (Figure 15). 
 
 
Break 
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Figure 13 – Missense mutation in SDHB exon 1 (c.32G>A; p. R11H) in APFC patient. 
 
 
 
Figure 14 – Frameshift mutation in SDHB exon 6 (c.591 del.C; p.S198AfsX22) in PMOV patient. 
 
 
 
Figure 15 – Missense mutation in SDHD exon 1 (c.3 G>C; p.M1I) in AEMS patient. (reverse sequence) 
 
Since previous studies from our group had found a high prevalence of the large SDHB deletion, 
haplotype analysis was performed to address whether this deletion had a founder effect in 
Portuguese patients. For that matter, the up- and downstream flanking regions of the deleted allele 
were sequenced and the status of already annotated SNP’s was determined (Figure 16). It was 
observed that the deleted allele had no haplotypic variation, comparing with control population that 
showed six different haplotypes (Table 11). 
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Table 11 – Haplotypes detected in the control population. 
Haplotypes 
SNP’s Frequency (%)  
n=100 chr rs1569754 rs3946080 rs2143811 rs5772743 rs7545518 rs7545499 rs7536679 
Hap1 C A C A A A T 4.0 
Hap2 C A C A G G C 23.0 
Hap3* C A C - A A T 47.0 
Hap4 C A C - G G C 12.0 
Hap5 T G T A A A T 1.0 
Hap6 T G T A G G C 13.0 
* haplotype 3 is the one present in the deleted alleles 
 
 
 
 
 
 
 
 
ins A 
2-3 CA 
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Figure 16 – Location of the SNP (arrows) used to define the haplotype of the SDHB large deletion comprising exon 1 and 
promoter. 
 
 
Furthermore, we decided to analyse PMFS patient for mutations in MAX gene as it had familial 
history, young age and a bilateral PCC. A nonsense mutation in MAX exon 3 was detected (c.97C>T; 
p.R33X), resulting in a premature stop codon and a truncated protein (Figure 17).  
 
 
Figure 17 – Nonsense mutation in MAX exon 3 (c.97C>T; p.R33X) from PMFS patient. 
 
In this series of 12 PGL/PCC’s, five different pathogenic variants were uncovered in six patients 
(50%), four of them point mutations (80%) - two missense mutations (50%), one nonsense mutation 
(25%) and one frameshift mutation (25%) -, and one large deletion (20%) present in two patients. 
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Three out of five mutations occurred in the SDHB gene (60%), one in SDHD gene (20%) and another 
one in MAX gene (20%). 
Two non-pathogenic variants were also identified, both in SDHB gene: the first one in exon 1 (c.18 
C>A; p.A6A) occurring in two patients, one with head and neck PGL (APFC) and carrying also a 
missense mutation (c.32 G>A; p.R11H) and the other one with PCC (PJSA) (Figure 18); the second 
variant was located in exon 5 (c.487 T>C; p.S163P) and showed up in one patient with pancreatic PGL 
(BMSO) (Figure 19).  
 
 
Figure 18 – SNP in SDHB exon 1 (c.18 C>A; p.A6A) from APFC and PJSA patients. 
 
 
 
Figure 19 - SNP in SDHB exon 5 (c.487 T>C; p.S163P) from BMSO patient. 
 
Table 12 summarizes all genetic variants carried by this series of 12 PCC/PGL’s. So, seven different 
genetic variants were found in this series of PGL/PCC patients, five of them pathogenic mutations 
(71%) and two non-pathogenic point mutations (29%). In total, eight patients (67%) carried at least 
one genetic variation, five of them as PGL cases (63%) and three PCC’s (37%). 
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Table 12 – Genetic variants carried by PGL/PCC patients. 
Clinical features SDH mutations 
MAX mutations 
I.D. Sex Age Tumour 
Additional 
features 
SDHB SDHD 
Exon 
Nucleotide 
change 
Protein change Exon 
Nucleotide 
change 
Protein 
change 
Exon 
Nucleotide 
change 
Protein 
change 
HMO F 44 PCC Malignant - - - - - - - - - 
APFC M 35 HN PGL - 1 
c.18 C>A 
c.32 G>A 
p.A6A 
p. R11H 
- - - - - - 
PMFS M 28 Bilateral PCC 
Index case – 
father 
- - - - - - 3 c.97C>T p.R33X 
AEMS M 15 PGL 
Index case – 
mother 
- - - 1 c.3 G>C p.M1I - - - 
MASC F 53 HN PGL - 1 + promoter 
c.1-10413_73-
3866del 
Exon 1 deletion - - - - - - 
MAMR M 15 PCC Malignant 1 + promoter 
c.1-10413_73-
3866del 
Exon 1 deletion - - - - - - 
IMPS F 42 PCC - - - - - - - - - - 
MJCBS F 52 PCC - - - - - - - - - - 
MRPT F 57 HN PGL - - - - - - - - - - 
BMSO F 56 Pancreas PGL - 5 c.487 T>C p.S163P - - - - - - 
PMOV M 31 
Retroperitoneal 
PGL 
- 6 c.591 del.C p.S198AfsX22 - -  - - - 
PJSA M 63 PCC - 1 c.18 C>A p.A6A - - - - - - 
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Genotype-phenotype correlation 
In order to correlate the genotype with the phenotypic presentation of the disease, the clinical 
features of patients with germline mutations were compared with those of patients without germline 
mutations (Table 13). Mutated patients were also divided according to the mutated gene; only SDHB 
mutated patients were compared with non-mutated cases as SDHD and MAX positive cases 
comprised only one patient. 
Non-mutated cases were more frequently female (83%) than male patients (17%), had a mean age 
at diagnosis of 52 years and more frequently developed PCC’s (67%) than PGL’s (33%). On the other 
hand, mutated cases had an inversion in sex ration and tumour location compared with non-mutated 
cases. They comprised more male (83%) than female patients (17%) and more PGL’s (67 %) than PCC 
cases (33%); mean age at diagnosis was significantly (p=0.006) lower in mutated cases than in non-
mutated cases (30 vs. 52 years, respectively).  
Comparing SDHB mutated cases with non-mutated ones, more male (75%) than female patients 
(25%) were affected, with a mean age of 34 years old and comprising more PGL’s (75%) than PCC 
tumours (25%). Significant differences appeared for mean age at diagnosis, as SDHB mutated cases 
had younger ages than non-mutated cases (p=0,035). 
There were two malignant tumours in this series, one in a patient without germline mutations and 
another in a patient with a SDHB large deletion (c.1-10413_73-3866del).  
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Table 13 – Correlation between non-mutated patients with all mutated and SDHB mutated patients. 
Clinical features 
Non-
mutated 
patients 
(n=6) 
Mutated patients P-value 
All 
mutated 
patients 
(n=6) 
SDHB 
mutated 
patients 
(n=4) 
SDHD 
mutated 
patient 
(n=1) 
MAX 
mutated 
patient 
(n=1) 
Non-mutated 
Vs Mutated 
patients 
Non-mutated 
Vs SDHB 
mutated 
patients 
Gender 
F 
M 
 
5 (83%) 
1 (17%) 
 
1 (17%) 
5 (83%) 
 
1 (25%) 
3 (75%) 
 
0 
1 (100%) 
 
 
1 (100%) 
p=0,080 p=0,190 
Mean Age 52 30 34 15 28 p=0,006 p=0,035 
Tumour Location 
PGL 
Head and Neck 
Pancreas 
Retroperitoneal 
Extra-adrenal 
PCC 
Bilateral 
 
2 (33%) 
1 (50%) 
1 (50%) 
0 
0 
4 (67%) 
0 
 
4 (67%) 
2 (50%) 
0 
1 (25%) 
1 (25%) 
2 (33%) 
1 (100%) 
 
3 (75%) 
2 (67%) 
0 
1 (33%) 
0 
1 (25%) 
0 
 
1 (100%) 
0 
0 
0 
1 (100%) 
0 
0 
 
0 
0 
0 
0 
0 
1 (100%) 
1 (100%) 
p=0,567 p=0,542 
Malignancy 1 (14%) 1 (20%) 1 (25%) 0 0   
Polymorphic variants were excluded for this analysis  
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6. DISCUSSION 
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This Thesis aimed to progress in the understanding of the molecular genetics of PCC and PGL, 
taking into account that PCC and PGL are the human neoplasias with the largest number of 
susceptibility genes. We have studied two different populations, one from Poland – composed of PCC 
- and another from Portugal – composed of PCC and PGL. 
 
The first aim was to identify loss of SDH enzyme expression in the tumour tissue from the Polish 
PCC series. After discovering three cases with loss of SDH expression, these were picked for SDH 
mutation screening, in order to explain the absence of protein expression. Indeed, two cases with 
absent SDH expression carried large deletions in SDH genes, specifically SDHD exon 4 and SDHC exon 
4B. However, only SDHD exon 4 deletion was considered a mutation, since SDHC exon 4B probe is 
extremely variable and can easily be affected by a SNP carried by the target sequence (that we did 
not assess). Besides, one of the samples with negative SDHB immunostaining carried both the SDHD 
exon 4 deletion (which was confirmed three times, with different probesets of the MLPA reaction) 
and the SDHC exon 4B deletion (that only appeared once), making the SDHC 4B deletion a probable 
artefact. Thus, this exon 4B deletion in SDHC was not considered as a true genetic variant.  
The deletion encompassing SDHD exon 4, results in the removal of the terminal coding exon which 
might explain the absence of SDH expression. Mitochondrial complex II has two cytochrome b 
subunits composed of large (cybL – SDHC) and small (cybS – SDHD) subunits that act as hydrophobic 
membrane anchor peptides and are essential for the interaction between the complex and quinone 
species. Each one has three transmembrane helices (I, II, III, and IV, V, VI): helices II and V provide a 
histidine ligand to the heme closest to the [3Fe-4S] cluster within SDHB; and helices I and IV provide 
the histidines for lower potential heme located towards the membrane surface (Hirawake et al. 1999; 
Ackrell 2000). SDHC and SDHD proteins also contain two ubiquinone-binding sites (Horsefield et al. 
2006; Welander et al. 2011; Fishbein et al. 2012). 
Thus, the removal of the terminal coding exon from SDHD gene will possibly result in alterations of 
protein transmembrane helices, consequently changing the attachment of SDHB and SDHA to the 
inner membrane and modifying the electrons transfer from iron-sulphur clusters within SDHB. As 
ubiquinone-binding sites within SDHC and SDHD can also be affected, the final acceptor ubiquinone 
will possibly be unable to accept electrons transferred from flavin by iron-sulphur clusters. Thus, 
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electron transport chain will be deficient or blocked, resulting in absent generation of an 
electrochemical proton gradient across the inner membrane of mitochondria, which is essential for 
ATP synthesis in the oxidative phosphorylation (Lodish et al. 2000). As complex II couples the 
oxidation of succinate to fumarate with the reduction of quinone to quinol, in the Krebs cycle and in 
the electron transport chain, respectively, the referred changing events might also abolish association 
between these two metabolic processes.  
 
A large deletion in SDHD exon 4 was reported by Janecke et al. in two familial PGL’s from Austria 
with a founder effect. This was the first large SDHD deletion characterized at the sequence level. This 
gross deletion removes the terminal coding exon within a region of high Alu content. Human genome 
has only 10% of Alu repeats and they constitute 24% of the SDHD genomic sequence, between the 
gene transcription start site and the end of terminal coding exon; 42% of the genomic sequence is 
flanking the terminal exon of SDHD, where the breakpoint of the deletion occurred. As Alu-mediated 
recombination events are responsible for large germline deletions, high Alu content in the terminal 
coding exon of SDHD might be implicated in the pathogenesis of the deletion (Janecke et al. 2010). 
Large germline founder deletions in SDHB and SDHC were found in Spain and United States (Baysal 
et al. 2004; Cascón et al. 2008; Ricketts et al. 2010); in SDHD gene, so far, only single nucleotide 
changes or small deletions and insertions were described as founder mutations in SDHD gene, first in 
the Netherlands and more recently in the United States, Italy, Spain and China (Taschner et al. 2001; 
Baysal et al. 2002; Lee et al. 2003; Simi et al. 2005; Velasco et al. 2005). The large deletion in SDHD 
exon 4 identified in a PCC Polish patient could be the same deletion reported by Janecke et al. and 
perhaps with a founder effect extensible from Austrian to Polish population; however further studies 
are needed to confirm the deletion breakpoint and variation in the flanking regions of the deleted 
allele.  
Only one sample was found to have a SDH mutation, after screening for point mutations, as well 
as small and large deletions in all SDH genes. The only exception was SDHA that was not analysed 
since its expression was retained in the tumour tissue, discarding possible mutations. We are 
therefore missing the alternative events that are on the basis of loss of SDH expression in two PCC, 
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which may include deleterious mutations in untranslated, intronic, or promoter regions of the genes, 
or epigenetic silencing of SDH genes. 
 
In addition to the three cases with SDH loss, seven cases had familial history compatible with 
syndromic disease: four patients were diagnosed with NF1 based on clinical criteria, two cases had 
clinical feature related with MEN2 syndrome and were further diagnosed by RET genetic testing, and 
the case with VHL syndrome, was screened for mutations in VHL gene.  
Patients with MEN2 carried missense mutations in RET gene: one located in exon 11 (c.1901G>A, 
p.C634Y) and the other one in exon 16 (c.2753T>C, p.M918T). These two mutations were already 
reported and constitute the most common pathogenic genetic variants underlying MEN2A and 
MEN2B syndromes, respectively (Carlson et al. 1994; Mulligan et al. 1994). 
In the VHL patient, PCR amplification of tumour DNA for VHL gene was not possible, which may 
suggest a complete loss of VHL gene in the tumour tissue. According to the Knudson two-hit model, 
biallelic VHL inactivation due to mutation or hypermethylation is a common event in 
hemangioblastomas and clear-cell renal carcinomas. Normally, in sporadic tumours both the first and 
second “hit” occur somatically rather than in the germline. However, in apparently sporadic PCC’s, 
germline VHL mutations are not as rare as in clear-cell renal carcinoma or hemangioblastoma and 
somatic VHL mutations are rare in truly sporadic PCC’s. It is unknown why some germline VHL 
mutations lead to PCC and yet somatic VHL mutations are rare. Although the reasons are still unclear, 
this might suggest that VHL inactivation during a critical developmental window or VHL 
haploinsufficiency results in PCC formation in the setting of VHL disease (Kim et al. 2004; Nakamura et 
al. 2006). 
Almost all VHL type 2 patients (high risk of PCC) harbour VHL missense mutations, whereas null 
VHL alleles cause type 1 disease (low risk of PCC). This suggests that complete loss of VHL protein 
function is incompatible with PCC development or that PCC reflects a gain-of-function mutant VHL 
protein (Nakamura et al. 2006). As complete loss of VHL gene in PCC is thought to be a very rare 
event, we can speculate that probably the absent amplification of VHL gene was due to poor tissue 
quality. 
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This series thus comprised 10 mutated and 47 non-mutated PCC patients, which means that in 
18% patients the cause for tumour development was an inherited genetic mutation. Genotype-
phenotype correlations showed that mutated patients were more frequently males, comparing with 
non-mutated cases that were mostly female patients. Also, mutated patients had younger age at 
diagnosis than non-mutated ones, even though NF1 patients had higher mean age at diagnosis than 
other mutated patients. The VHL patient had the lowest age at diagnosis. 
It is known that tumours among patients with VHL, SDHB and SDHD mutations have lower ages at 
diagnosis compared with those with MEN2 and NF1 syndromes (Eisenhofer et al. 2011). In fact, in our 
findings, VHL patient had the lowest age and NF1 patients had the higher mean age at diagnosis. 
Periodic screening for germline mutations related to PCC/PGL’s contributes to the younger age at 
diagnosis, both for patients with familial history or with sporadic disease. (Eisenhofer et al. 2011) As 
NF1 gene has no hotspot for genetic screening, clinical features analysis might delay diagnose of this 
patients resulting in higher ages at diagnosis.  
Differences in the age at diagnosis are also associated with different catecholamine phenotypes of 
tumours. Epinephrine-producing tumours (MEN2 and NF1) are associated with later ages at diagnosis 
than those that do not produce epinephrine (SDH and VHL). This can be explained by the differences 
in signs and symptoms caused by different catecholamine phenotypes. Other explanation is that 
tumourigenic processes for PCC/PGL development involve blocked differentiation of chromaffin 
progenitor cells during embryonic development and failure of neuronal apoptosis. Epinephrine-
producing chromaffin cells develop later in embryogenesis and thus, tumourigenic processes 
associated with fully differentiated epinephrine-producing chromaffin cells occur later in 
embryogenesis or even after birth, leading to later onset of PCC/PGL; in contrast, tumourigenic 
processes associated with chromaffin progenitors lacking epinephrine production initiate earlier in 
embryogenesis, resulting in earlier onset of disease (Eisenhofer et al. 2011). 
In contrast, SDH patients had higher mean age at diagnosis than MEN2 patients, which is not in 
agreement with previous reports. Earlier ages at diagnosis by MEN2 patients might be explained by 
the presence of bilateral tumours compared with SDH patients with unilateral PCC’s. Multifocal 
tumours origin can be explained by single tumour stem cells occurring during embryogenesis and 
resulting in an earlier onset of PCC than those normally occurring later in life (Eisenhofer et al. 2011). 
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We have also observed that bilateral tumours developed only in mutated patients, specifically in 
MEN2 cases and in one NF1 patient. According to several reports, indeed familial PCC/PGL’s are more 
likely to develop bilateral tumours and several reports indicate that MEN2 associated PCC’s are more 
often bilateral (50%); NF1 patients develop bilateral PCC’s more rarely (14%) (Welander et al. 2011; 
Young et al. 2012). 
Mean tumour size was higher for non-mutated cases, but not with significant differences 
compared with mutated cases. Mean tumour size for both groups relies in small PCC’s category, as it 
was defined that tumours below 6cm are considered small sized and those above or equal 6cm are 
large tumours (Agarwal et al. 2010). In addition, some reports defined that PCC’s below 6cm are 
considered probable benign and those above or equal to 6cm are probable malignant tumours 
(Goldstein et al. 1999). In our series, patients with metastasis had a mean tumour size of 9cm, which 
supports this theory. However, increased size alone, although suggestive for malignancy, is not a 
good predictor of differences in biological behaviour of tumours (Agarwal et al. 2010). 
Among the mutated tumours the largest ones were seen in NF1 patients and the smallest was the 
VHL tumour. In fact, NF1 protein is implicated in the GTPase activity to convert Ras into its inactive 
form, inhibiting Ras/Raf/MAPK signalling pathway, thus suppressing cell growth; on the other hand, 
mutant protein does not activate Ras which becomes constitutively activated to trigger the 
subsequent oncogenic downstream pathways (MAPK, PI3K and mTOR) responsible for cell 
proliferation and differentiation, thus leading to uncontrolled cell proliferation (Boyd et al. 2009; 
Welander et al. 2012). This mechanism could explain the large size of NF1 tumours comparing to SDH, 
MEN2 or VHL tumours. 
Metastasis appeared only in non-mutated cases and relapse in only one mutated patient, 
contrarily to what was expected, as mutated patients have more predisposition to develop malignant 
tumours. Mutations in the SDHB gene are the most frequently associated with metastatic PCC/PGL’s, 
predicting tumour aggressiveness and poor survival of patients, although a causal link has not been 
established yet. Nevertheless, the majority of patients with metastatic tumours do not carry 
mutations in any gene associated with PCC/PGL and our series of PCC’s supports this. Sporadic PCC’s 
could display increased angiogenesis, hypoxia and extracellular matrix elements in addition to 
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suppression of oxireductase enzymes and increased intracellular HIF concentrations that might 
explain malignancy (Ayala-Ramirez et al. 2011). 
Both mutated and non-mutated patients had a mean PASS score of 4, indicating a possible 
aggressive behaviour of these tumours and suggesting that in this series PASS score probably is not a 
good predictor to associate malignancy with mutations.  
Finally, microvessel density was smaller for mutated cases comparing with non-mutated. 
Microvessel density has been suggested to be a predictor of metastatic disease and to associate with 
tumour aggressiveness; this is reflected in our series, as mutated patients had non-metastatic 
tumours and lower microvessel density. 
Metastatic tumours have been found to display a higher number of vessels compared with non-
metastatic tumours (Weidner 1995). Among the angiogenic factors, vascular endothelial growth 
factor (VEGF) is a particular regulator of angiogenesis that is secreted by tumour cells. VEGF gene 
expression had previously been reported in PC12 pheochromocytoma cells and may be useful as a 
prognostic marker since its levels help distinguish benign from malignant tumours. In fact, higher 
VEGF expression and microvessel density was found in malignant compared with benign human PCC’s 
(Zielke et al. 2002). 
 
The second part of this study involved the screening of SDH mutations in 12 genomic DNA samples 
from PCC/PGL patients. In this series, six cases carried five different pathogenic mutations underlying 
PCC/PGL development, four of them in SDH genes and one in MAX gene, resulting in 50% patients 
whose cause for tumour development was an inherited genetic mutation. 
Two patients were found to carry a large deletion in SDHB gene encompassing exon 1 and 
promoter (c.1-10413_73-3866del) which presumably leads to loss of the promoter or an abnormal 
protein due to alternative start codon. This alteration had already been identified by Cascón et al. in 
patients from the northwest of the Iberian Peninsula. The authors proposed a founder effect for this 
alteration, since all the patients showed a conserved breakpoint and conserved SNP flanking the 
deletion (Cascón et al. 2008). Notably, of the five families, one was from Porto, Portugal, a second 
was a Brazilian family and the remaining three were of Spanish origin, more specifically from Galicia, 
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close to the border with northern Portugal (Cascón et al. 2008). Recently, 11 Portuguese patients 
have also been identified with this large deletion. Results of this study showed that the deletion 
breakpoint matches the previously found by Cascón et al. and that the deleted allele from all 11 
patients shares the same haplotype, evidencing a common origin of this pathogenic mutation carried 
by northern Portuguese patients.  
The second mutation, a missense mutation in exon 1 of SDHB gene (c.32G>A, p. R11H), had been 
previously described by Ricketts et al. in a patient with renal cell carcinoma with no familial or 
personal history of PCC/PGL (Ricketts et al. 2008); however, the patient here described does not have 
signs of disease other than PGL, raising the question of what are the reasons behind the varying 
expressivity of SDHB mutations in different patients. In fact, several tumours have been associated 
with SDHB mutations: PCC and PGL are the most common, but also gastrointestinal stromal tumours 
(GIST), breast and papillary thyroid carcinoma (PTC), neuroblastoma, renal cell carcinoma (clear-cell 
and papillary RCC) and Carney-Stratakis syndrome (dyad of gastrointestinal stromal tumours and PGL) 
are also found in SDHB mutated patients (Bardella et al. 2011). 
The frameshift mutation in exon 6 of SDHB gene (c.591 del.C; p.S198AfsX22) had been previously 
reported by Astuti et al. in a sporadic PCC patient (Astuti et al. 2001). Subsequent studies by Gimenez-
Roqueplo, Benn and Fakhry found the same mutation in PGL patients (Gimenez-Roqueplo et al. 2003; 
Benn et al. 2006; Fakhry et al. 2007). The outcome of the mutation is a complete loss of mitochondrial 
complex II enzymatic activity, as further molecular and enzymatic analysis showed abnormal 
succinate cytochrome c reductase and quinol cytochrome c reductase activity. (Gimenez-Roqueplo et 
al. 2003) 
The missense mutation in exon 1 of SDHD gene (c.3 G>C; p.M1I) was firstly reported by Badenhop 
et al. in a familial carotid body PGL (Badenhop et al. 2001). This mutation affected the first codon, 
blocking the initial methionine translation and thus protein formation. 
Additionally, two non-pathogenic variants were identified - c.18 C>A; p.A6A and c.487 T>C; 
p.S163P -, both in SDHB gene constituting single nucleotide polymorphisms already reported by 
Cascón et al. and with a frequency of 4% and 2-3%, respectively, in the European population (Cascón 
et al. 2002). In this study, the frequency for the first SNP in exon 1 was 17% and for the second SNP in 
exon 5 was 8%, both higher than European frequencies.  
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Among SDH genes, SDHB and SDHD are known to be the most mutated ones and this series 
supports this fact. 
Genotype-phenotype correlations showed that SDH mutated cases comprised more male than 
female patients and more PGL’s than PCC’s. SDH mutated patients often present more PGL’s than 
PCC’s, as it was also shown in this series. Mean age at diagnosis was lower in mutated patients 
compared to non-mutated patients, as expected, since mutations predispose to earlier formation of 
tumours. One malignant tumour was identified as carrying a SDHB large deletion, supporting the fact 
that SDHB has high potential of malignancy compared to other SDH genes. 
 
The mechanisms behind the tumourigenesis induced by SDH mutations are still under study. It is 
known that the mitochondrial enzyme complex – SDH - is the only one involved both in the electron 
transport chain and in the Krebs cycle (Horsefield et al. 2006; Fishbein et al. 2012). The main functions 
of SDH enzyme include catalyzing the oxidation of succinate to fumarate in the Krebs cycle and also 
electrons transfer to the terminal acceptor ubiquinone or coenzyme Q in the electron transport chain, 
reducing it to ubiquinol (Horsefield et al. 2006; Welander et al. 2011; Fishbein et al. 2012). 
Inactivation of SDH complex subunits has been found to result in the accumulation of succinate 
and also an increased production of oxygen free radicals (Karasek et al. 2010). Accumulated succinate 
moves out from the mitochondria, through the dicarboxylate carrier, to the cytosol, where it is able 
to inhibit the activity of HIFα prolyl hydroxylases (PHD’s) like EglN1 and EglN3, causing a pseudo-
hypoxic phenomenon (Smith et al. 2007). In normoxic conditions, PHD’s hydroxylate two proline 
residues on HIFα, using α-ketoglutarate and oxygen as substrate and iron and ascorbate as co-factors. 
Thus, HIFα is recognized and targeted by VHL protein to oxygen-dependent ubiquitination by an 
ubiquitin ligase complex and consequently degraded in the proteasomal system (Bardella et al. 2011). 
However, when high levels of succinate inhibit PHD’s, HIFα is not hydroxylated and subsequently 
escapes proteasomal degradation. This event leads to migration of HIFα from the cytosol to the 
nucleus, where it forms a heterodimer with HIFβ, causing an induction of expression of genes 
responsible for glycolysis, angiogenesis, proliferation and cell survival (Bardella et al. 2011); this 
phenomenon, where HIF is stabilized even in normoxia is termed pseudo-hypoxia. Numerous studies 
support this mechanism of tumourigenesis for PCC/PGL’s development. In fact, angiogenic profile of 
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the tumours has been seen in complete loss of complex II function due to HIF deregulation (Bardella 
et al. 2011). 
Another explanation for tumourigenesis caused by loss of function of SDH enzyme is the 
production of reactive oxygen species (ROS) in the electron transport chain. Although complex II is 
not a major local for ROS production, SDH mutations induce oxidative stress, genomic instability and 
tumourigenesis. Studies in model organisms, like mouse, worm and yeast showed that mutations 
affecting the ability to catalyze the electron transport from succinate to ubiquinone lead to electrons 
leakage and oxygen hypersensitivity phenotype with consequent elevation in oxidative stress, 
increased levels of ROS production and tumour growth. ROS can inhibit PHD’s activity by oxidation of 
co-factors like ferrous iron and ascorbate resulting in a pseudo-hypoxic response (Bardella et al. 
2011). The hypothesis of ROS being the link between SDH mutations and tumour development is 
under debate, since some studies showed no increased ROS production upon SDHB inactivation, but 
only an up-regulation of HIF-1α and HIF-2α. However, several other reports showed increased ROS 
production upon SDH mutations. The contrasting observations regarding ROS production, due to 
biological or technical reasons is to be determined (Bardella et al. 2011). 
The third hypothesis for PCC/PGL’s formation is a reduced apoptosis of sympathetic neuronal cells 
that carry SDH mutations, during embryogenesis. This apoptotic process is mediated by prolyl 
hydroxylase PHD3, which is inhibited due to succinate accumulation (Bardella et al. 2011). 
Another supported theory is that accumulated succinate might inhibit other components of the α-
ketoglutarate-dependent dioxygenase family, besides the PHD’s and resulting in cell transformation 
and tumourigenesis. This family comprises enzymes involved in several biological roles, such as 
histone and nucleic acid demethylation. Histone demethylases inhibition can result in altered 
expression of oncogenes and tumour suppressor genes, such as those responsible for DNA repair, 
induction of apoptosis and growth inhibition (Bardella et al. 2011). As histone demethylases regulate 
some genes by recruitment of specific proteins, they have an impact in chromatin structure and gene 
expression and therefore, an epigenetic event might be specific for PCC/PGL’s syndrome (Bardella et 
al. 2011). Succinate can thus act as messenger between mitochondria and cytosol as well as signal 
between mitochondria and nucleus, regulating gene expression (Bardella et al. 2011). 
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Finally, the G-protein-coupled GPR91 receptor might also be involved in the PCC/PGL’s 
tumourigenic process. It was shown that succinate can act as ligand for GPR91 in the Krebs cycle, 
resulting in unexpected signalling functions, such as mediating vessel growth through the release of 
proangiogenic factors (like VEGF). Accumulated succinate leads to the deregulation of GPR91 causing 
sustainment of signalling pathway and stimulation of endothelial cells proliferation. Thus, altered 
levels of succinate, through the activation of its receptor GPR91, can promote tumour onset and 
progression (Bardella et al. 2011). 
The induction of tumourigenesis triggered by SDH mutations represents an example of the 
importance of metabolic alterations in tumour development. Regarding cancer metabolism, a well-
known feature is the “Warburg Effect” where malignant cells use aerobic glycolysis to generate 
energy instead of mitochondrial oxidative phosphorylation like normal cells (López-Lázaro 2008; 
Welander et al. 2011). Hypoxic conditions observed in tumours can exacerbate the upregulation of 
glucose transporters and other multiple enzymes of the glycolytic pathway. Therefore, hypoxia can 
raise the HIF1α and HIF2α transcription factors levels, independently, which then upregulate 
glycolysis, leading to active cell proliferation (Hanahan et al. 2011; Fliedner et al. 2012). 
Mutations of SDH subunits have been shown to cause activation of hypoxic response, even in 
normoxic conditions, a process referred as pseudo-hypoxia. Tumourigenesis is also associated with 
glycolytic phenotype of tumours, since the Warburg effect takes place when SDH mutations lead to 
impaired oxidative phosphorylation and Krebs cycle in PCC/PGL’s. First, electron transport chain by 
complex II is impaired in oxidative phosphorylation and second, compromised conversion of succinate 
to fumarate leads to increased amounts of succinate which inhibits PHD’s and causes HIF’s activation. 
HIF-responsive genes are then activated reinforcing glycolysis, while oxidative phosphorylation is 
decreased (Favier et al. 2009; Fliedner et al. 2012). 
 
Recently, Rapizzi et al. studied a series of 57 PGL patients to evaluate SDH activity and expression 
and mitochondrial homeostasis (Rapizzi et al. 2012). It was the first systematic study in PGL’s about 
SDH activity and expression, only reported so far in a patient with SDHD mutation and two cases with 
SDHB and SDHA mutations that result in lack of SDH activity, as well as in 22 head and neck PGL’s 
(Gimenez-Roqueplo et al. 2001; Dekker et al. 2003; Burnichon et al. 2010). The results showed 19 
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germline mutations (ten SDHD, three SDHB, one SDHC, two RET, one VHL and two MAX) and two 
somatic mutations (SDHD) among the PGL cases. All SDH-mutated tumours displayed decreased SDH 
activity, as well as one case of MAX-mutated PGL and two wild-type cases at peripheral DNA genetic 
analysis that were then found to have SDHD somatic mutations (p.Asp113MetfsX21 already described 
by Cascón et al. and a novel mutation p.Leu7CysfsX7). RET and VHL mutated tumours displayed 
normal SDH activity. LOH was found only in 70% of the patients with a decreased SDH activity and 
expression (Rapizzi et al. 2012). 
RT-PCR study on the four SDH subunit transcript levels was performed to discover the mechanism 
underlying decreased SDH activity and expression in one of the two MAX-mutated tumours 
(p.Leu94Pro). In the MAX-mutated tissue, the transcript levels of SDHB, SDHC, and SDHD were slightly 
increased compared with control; the authors suggested that SDH complex instability and 
disassembling rather than a negative transcriptional regulation were involved in SDH decreased 
expression in the MAX-mutated tissue (Rapizzi et al. 2012). 
To address the differences in SDH activity and expression, the authors analysed citrate synthase 
(CS) activity, an enzyme present in the mitochondrial matrix and involved in the TCA cycle, voltage-
dependent anion channel (VDAC) expression, a protein located on mitochondria outer membrane, 
and cytochrome c oxidase (COX) activity, an enzyme of the respiratory chain located in the inner 
mitochondrial membrane as mitochondrial complex IV. The results showed normal activity for CS and 
VDAC elements and extreme variability of COX activity among the different tissue samples. Thus, CS 
analysis suggested that enzyme function within the mitochondrial matrix was not impaired by the 
presence of SDH mutations. VDAC and COX were investigated, since preliminary data on SDH-
mutated PGL’s suggested a structural alteration of mitochondrial cristae. These observations 
suggested that in these tumours, neither the outer mitochondrial membrane, as shown by the normal 
VDAC expression, nor the mitochondrial matrix, as shown by the normal CS activity were modified 
and only the mitochondrial cristae were altered, as seen by COX activity (Rapizzi et al. 2012). 
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Figure 20 - Regulation of HIF. Inactivation of SDH, VHL, or EGLN1 are believed to cause a pseudo-hypoxic response where 
HIF-1α and/or HIF-2α escape ubiquitination and are allowed to accumulate (Welander et al. 2011). 
 
SDHAF2 gene was also screened in the Polish PCC series, with no mutations found. Nevertheless, 
mutations in this gene are also associated with alterations in SDH complex. 
In 1981 van Baars et al. described a Dutch family with a single nucleotide c.232G>A change in exon 
2, which caused G78R mutation in the most conserved region of the protein (Baars et al. 1981). 
Subsequently studies using affected individuals from different branches of the previously 
described Dutch PGL2 lineage identified the same mutation in SDHAF2 gene (Hao et al. 2009; Kunst et 
al. 2011). 
Flavination of SDHA had been proposed to require at least one additional protein, SDHAF2, which 
participates in the FAD attachment. SDHA flavination was decreased by 95% in tumours from three 
patients with PGL in comparison with control tumours from two sporadic PGL patients. Thus, G78R 
mutation destabilizes SDHAF2 and impairs its interaction with SDHA (Hao et al. 2009). 
Loss of SDHAF2 results in absence of SDH function and a reduction in the stability of the SDH 
complex, leading to reduced levels of all subunits (Kunst et al. 2011). 
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In the first part of this thesis, we aimed to identify mutations in the new susceptibility genes for 
PCC - MAX and TMEM127 - in patients without SDH, MEN2, VHL or NF1 syndromes. The genetic 
analysis of MAX and TMEM127 was difficult, with the appearance of false positive cases for 
pathogenic mutations in these two genes, possibly due to poor quality material.  
In the second part of the thesis, time constraints did not allow us to screen for MAX and TMEM127 
mutations in cases without SDH mutations. However, a PCC case belonging to a young patient with 
familial PCC history prompted us to screen for mutations in MAX gene, with consequent identification 
of a pathogenic nonsense mutation (c.97C>T; p.R33X). This nonsense mutation in MAX gene was 
reported by Comino-Mendez et al., which confirmed the lack of full-length MAX in the tumour 
carrying this genetic variant, by immunohistochemical analysis (Comino-Méndez et al. 2011). 
Although our series showed only one pathogenic mutation in the MAX gene, several reports 
identified MAX and TMEM127 genes as possible candidates for PCC pathogenesis. 
Comino-Mendez et al. used next-generation sequencing for MAX gene to analyse three 
independent familial PCC cases without a germline mutation in any known susceptibility gene. Three 
alterations were found and these PCC’s showed MAX protein loss of expression by 
immunohistochemistry and LOH by tumour DNA analysis. LOH in MAX gene was discovered to be 
caused by uniparental disomy (UPD) from paternal origin with loss of the maternal allele. In addition, 
paternal origin of the mutated allele was also detected in other six families, showing a preferentially 
paternal transmission of the disease (Comino-Méndez et al. 2011). 
More recently, a large series of 1694 unrelated PCC/PGL’s without evident germline mutations in 
RET, VHL, SDHB, SDHC, SDHD, and TMEM127 genes was screened for MAX gene. Results showed 23 
patients carrying 16 different heterozygous variants. Further 245 tumours were analysed and four 
somatic mutations were identified. Among these, 18 were novel variants, five of them disrupting MAX 
protein, 11 nontruncating variants, seven of them changing conserved or highly conserved amino 
acids located within the basic helixloop-helix leucine zipper (bHLH-Zip) domain of the MAX protein 
and four predicted as benign (Burnichon et al. 2012). 
Immunohistochemical analysis showed loss of MAX expression for all tumours carrying truncating 
mutations and positive protein staining in all nontruncating variants. LOH of the MAX wild-type allele 
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was found in 16 of 18 tumours. This study identified pathogenic germline MAX variants in 1% of the 
1694 cases, mostly in PCC patients but also in 3 PGL cases. Variants were more frequent in exons 3 
and 4, which comprise some of the most important residues within the conserved bHLH-Zip domain 
of MAX (Burnichon et al. 2012). 
Most of the mutations identified so far, affected highly conserved amino acids within the basic 
helix-loop-helix leucine zipper domain of MAX, the structural element for specificity and stability of 
homodimer and heterodimer formation, as well as DNA recognition. This domain is implicated in 
protein-protein interactions and DNA binding; alterations that affect bHLHZip domain could lead to 
impaired MAX function and tumour development (Cascón et al. 2012). 
Ribon et al. showed that MAX functions as regulator of MYC-dependent transcriptional activation. 
In the PC12 cells (derived from rat adrenal PCC), that have a homozygous alteration in the MAX gene, 
the encoded protein is uncapable of forming homodimers or heterodimers leading to the inhibition of 
transcriptional repression from E-box elements; reintroducing MAX in these cells caused 
transcriptional repression and reduced growth rate (Ribon et al. 1994). These findings also 
demonstrated that MYC functions in the absence of normally functioning MAX protein, proved later 
by Gallant et al. in Drosophila and leading to the conclusion that MAX is related more to repression 
than to activation (Gallant et al. 2009). 
MAX tumours, when compared with PCC/PGL’s with mutations in other genes, showed significant 
enhancement of mTOR pathway components. This finding revealed that MAX mutations not only 
deregulate MYC function but also lead to altered mTOR pathway and PCC/PGL’s development (Cascón 
et al. 2012). In fact, PI3K/AKT/mTOR and MYC/MAX/MXD1 pathways were recently associated, since 
phosphorylated S6K1, activated by mTOR to regulate cell growth, inhibits the tumour suppressor 
function of MAD1, leading to deregulation of MYC, cell growth and activation of proliferation (Zhu et 
al. 2008). 
 
In addition to MAX, Qin et al. identified TMEM127 gene as a novel PCC susceptibility gene. 
Sequencing 102 PCC cases, 19 with familial history and 83 as sporadic cases, seven germline 
mutations were detected. Four were detected in 12 families and the other three were identified 
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among the sporadic cases, all of them without mutations in other PCC susceptibility genes. Six 
mutations were splice-site or nonsense mutations and were associated with interruption of protein 
reading frame. Also, LOH was proved to occur at TMEM127 locus with loss of the wild type allele 
leading to the conclusion of TMEM127 being a classic tumour suppressor gene (Qin et al. 2010). 
In a subsequent study Qin et al. considered a group of 990 samples from PCC/PGL patients without 
mutations in other susceptibility genes to analyse possible germline mutations in TMEM127 gene. 
Thirteen novel changes were found and six variants previously reported comprising small deletions, 
duplications, insertions, nonsense mutations, splice site substitutions, nonsynonymous missense 
mutations and substitutions in the UTR region, all of them potentially pathogenic. Also, LOH was 
detected in four cases and no large deletions were found among 545 samples analysed. So, point 
mutations and small deletions/insertions are the main cause of TMEM127 deregulation, not excluding 
other hypotheses such as gene promoter methylation (Yao et al. 2012). 
All patients with TMEM127 mutations developed PCC, one-third of them with bilateral tumours; 
no PGL’s were found so far in TMEM127 mutated patients. The age of onset of mutated tumours was 
similar to patients with sporadic disease, which does not follows the earlier manifestation seen in 
hereditary PCC’s caused by mutations in other susceptibility genes. Only one patient carrying a 
missense mutation had metastases (Yao et al. 2012). 
Four novel truncating mutations, two of them nonsense and two other frameshift mutations were 
discovered by Abermil et al. in a French series of 642 unrelated patients with PCC/PGL. All mutated 
patients had PCC and secreted high levels of metanephrine, clustering TMEM127 tumours with 
epinephrine producing tumours like RET or NF1 tumours. Once more, no large deletions or 
duplications were detected in TMEM127, indicating that genetic testing should be restricted to direct 
sequencing (Abermil et al. 2012). 
Abermil et al. combined their data with Yao et al. and Neumann et al. studies, concluding that 
TMEM127 mutations had a prevalence of 2% among the 1676 patients reported until now (Abermil et 
al. 2012). 
TMEM127 gene in humans is expressed both in normal tissue and also in many cancer cell lines. 
Colocalization studies by Qin et al. showed that TMEM127 is present in vesicular organelles like 
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endosomes, Golgi and lysosomes. Also, TMEM127 was associated with the plasma membrane, mostly 
when endocytosis is inhibited and an increasing pH causes TMEM127 trapping in endosomal 
structures. So, this gene was linked with protein trafficking between plasma membrane and 
endomembrane organelles, like Golgi and lysosomes (Qin et al. 2010). Green fluorescent protein 
expression in a subsequent study showed diffuse distribution of mutated TMEM127 in the cytoplasm, 
different from the wild-type which is located mostly in plasma membrane and endomembrane 
organelles. This localization of mutated proteins can be associated with mTOR accessibility to its 
regulators (Yao et al. 2012). 
Qin et al. showed increased phosphorylation of 4EBP1 in some cell lines with TMEM127 
knockdown and cells were larger and proliferative, features consistent with mTORC1 functions. Also, 
TMEM127 overexpression was associated with reduced mTORC1 signalling and decreased cell 
proliferation. Moreover, increased phosphorylation of S6K in lysates from TMEM127 mutant PCC was 
detected. To determine a possible influence of TMEM127 in mTOR subcellular localization, confocal 
microscopy was used and showed the same intracellular domain occupied both by TMEM127 and 
active mTOR (Qin et al. 2010). 
 
Figure 21 – Signalling pathways putatively involved in PCC/PGL’s development. Activation of mTOR may constitute a 
mechanism for tumour development caused by mutations in RET, NF1, or TMEM127; MAX may control cell proliferation 
by forming dimers with MXD1 that antagonize the transcriptional activity of MYC (Welander et al. 2011). 
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Summarizing, VHL and SDH related PCC/PGL’s share a similar gene expression profile linked to 
hypoxia and angiogenesis, where a stabilization of HIF-1α and/or HIF-2α, under normoxic conditions, 
may play a central role in the pathogenesis. In contrast, RET, NF1, TMEM127 and MAX related 
PCC/PGL’s display a profile that can be linked to an activation of kinase signalling pathways, such as 
RAS/RAF/MAPK, PI3K/AKT and mTOR signalling pathways, promoting cell proliferation, growth and 
survival. 
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In this study, the aim was to identify the genetic defects in SDH, SDHAF2, MAX, TMEM127, RET 
and VHL that underlie the development of tumours of the paraganglionic tissue, termed 
pheochromocytomas and paragangliomas. 
The results in a series of 57 PCC patients revealed three cases with absence of SDH expression, but 
only one case with a detected mutation. The existence of mutations in other recently identified 
PCC/PGL susceptibility genes prompted the study of MAX and TMEM127 in cases without evidence of 
syndromic disease such as MEN2, NF1 or VHL – although no mutations were identified, the 
involvement of these genes cannot be excluded, since detection of large deletions was not 
performed. Concomitantly, expression studies for MAX and TMEM127 proteins were not executed 
and thus, despite of absent mutations, some PCC’s might had loss of protein expression caused by 
alterations that were not investigated in this study. 
The results in a series of 12 PCC/PGL patients revealed four cases with SDHB mutations, one case 
with a SDHD mutation and one case with a MAX mutation. MAX screening was only performed for 
one case with familial history and TMEM127 was not screened. Among the six non-mutated cases 
some might carry MAX or TMEM127 mutations that were not assessed.  
Genetic testing is proved to be the best approach in PCC/PGL diagnose, as ten known susceptibility 
genes have been identified so far, making these tumours more commonly associated with an 
inherited mutation than any other cancer type. Nevertheless, additional susceptibility genes probably 
remain to be discovered, as some families with PCC or PGL did not have an identified genetic cause 
and some apparently sporadic cases had young age at diagnosis and other features that point to 
inherited genetic alterations. 
Knowledge of the clinical features linked to different hereditary backgrounds can be crucial for 
decision making regarding treatment and surveillance. Much more learning about the germline and 
somatic genetics in PCC/PGL and insights into the biology of these tumours is essential to provide 
targets for therapeutics. 
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